<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Arch Dermatol Res</journal-id>
      <journal-title>Archives of Dermatological Research</journal-title>
      <issn pub-type="ppub">0340-3696</issn>
      <issn pub-type="epub">1432-069X</issn>
      <publisher>
        <publisher-name>Springer-Verlag</publisher-name>
        <publisher-loc>Berlin/Heidelberg</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">17497162</article-id>
      <article-id pub-id-type="pmc">1910890</article-id>
      <article-id pub-id-type="publisher-id">744</article-id>
      <article-id pub-id-type="doi">10.1007/s00403-007-0744-y</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Review</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version)</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name name-style="western">
            <surname>Nast</surname>
            <given-names>A.</given-names>
          </name>
          <address>
            <email>info@psoriasis-leitlinie.de</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kopp</surname>
            <given-names>I.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Augustin</surname>
            <given-names>M.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Banditt</surname>
            <given-names>K. B.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Boehncke</surname>
            <given-names>W. H.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Follmann</surname>
            <given-names>M.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff6">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Friedrich</surname>
            <given-names>M.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff7">7</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Huber</surname>
            <given-names>M.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff8">8</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kahl</surname>
            <given-names>C.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff9">9</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Klaus</surname>
            <given-names>J.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff10">10</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Koza</surname>
            <given-names>J.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff10">10</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kreiselmaier</surname>
            <given-names>I.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff11">11</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mohr</surname>
            <given-names>J.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff12">12</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mrowietz</surname>
            <given-names>U.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff11">11</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ockenfels</surname>
            <given-names>H. M.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff13">13</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Orzechowski</surname>
            <given-names>H. D.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff8">8</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Prinz</surname>
            <given-names>J.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff14">14</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Reich</surname>
            <given-names>K.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff15">15</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Rosenbach</surname>
            <given-names>T.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff16">16</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Rosumeck</surname>
            <given-names>S.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff9">9</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Schlaeger</surname>
            <given-names>M.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff17">17</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Schmid-Ott</surname>
            <given-names>G.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff18">18</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sebastian</surname>
            <given-names>M.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff19">19</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Streit</surname>
            <given-names>V.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff20">20</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Weberschock</surname>
            <given-names>T.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Rzany</surname>
            <given-names>B.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff9">9</xref>
        </contrib>
        <aff id="Aff1"><label>1</label>Division of Evidence Based Medicine (dEBM), Klinik f&#xFC;r Dermatologie, Venerologie, Allergologie, Charit&#xE9;&#x2013;Universit&#xE4;tsmedizin Berlin, Schumannstrasse 20/21, 10117 Berlin, Germany </aff>
        <aff id="Aff2"><label>2</label>St&#xE4;ndige Kommission Leitlinien der AWMF, c/o Philipps-Universit&#xE4;t Marburg, Institut f&#xFC;r Theoretische Chirurgie, Marburg, Germany </aff>
        <aff id="Aff3"><label>3</label>Universit&#xE4;tsklinikum Hamburg-Eppendorf, Klinik und Poliklinik f&#xFC;r Dermatologie und Venerologie, Hamburg, Germany </aff>
        <aff id="Aff4"><label>4</label>Klinik f&#xFC;r Dermatologie, Venerologie und Allergologie, Charit&#xE9;&#x2013;Universit&#xE4;tsmedizin Berlin, Berlin, Germany </aff>
        <aff id="Aff5"><label>5</label>Zentrum der Dermatologie und Venerologie, Klinikum der Johann Wolfgang Goethe Universit&#xE4;t, Frankfurt am Main, Germany </aff>
        <aff id="Aff6"><label>6</label>Division of Evidence Based Medicine (dEBM), Klinik f&#xFC;r Dermatologie, Venerologie und Allergologie, Charit&#xE9;&#x2013;Universit&#xE4;tsmedizin Berlin [since 1 February 2005: Institut f&#xFC;r Qualit&#xE4;t und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)], Cologne, Germany </aff>
        <aff id="Aff7"><label>7</label>Klinik f&#xFC;r Dermatologie, Venerologie und Allergologie, Charit&#xE9;&#x2013;Universit&#xE4;tsmedizin Berlin [since 1 January 2006: Intendis GmbH], Berlin, Germany </aff>
        <aff id="Aff8"><label>8</label>Institut f&#xFC;r Klinische Pharmakologie und Toxikologie, Charit&#xE9;&#x2013;Universit&#xE4;tsmedizin Berlin, Berlin, Germany </aff>
        <aff id="Aff9"><label>9</label>Division of Evidence Based Medicine (dEBM), Klinik f&#xFC;r Dermatologie, Venerologie, Allergologie, Charit&#xE9;&#x2013;Universit&#xE4;tsmedizin Berlin, Schumannstrasse 20/21, 10117 Berlin, Germany </aff>
        <aff id="Aff10"><label>10</label>Deutscher Psoriasis Bund e.V, Hamburg, Germany </aff>
        <aff id="Aff11"><label>11</label>Klinik f&#xFC;r Dermatologie, Venerologie, Allergologie, Universit&#xE4;tsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany </aff>
        <aff id="Aff12"><label>12</label>Abteilung Dermatologie und Venerologie, Hautklinik und Poliklinik der Georg-August-Universit&#xE4;t G&#xF6;ttingen, G&#xF6;ttingen, Germany </aff>
        <aff id="Aff13"><label>13</label>Haut- u. Allergieklinik, Klinikum Hanau, Hanau, Germany </aff>
        <aff id="Aff14"><label>14</label>Klinik und Poliklinik f&#xFC;r Dermatologie und Allergologie, Klinikum der Ludwig Maximilian Universit&#xE4;t M&#xFC;nchen, Munich, Germany </aff>
        <aff id="Aff15"><label>15</label>Abteilung Dermatologie und Venerologie, Hautklinik und Poliklinik der Georg-August-Universit&#xE4;t G&#xF6;ttingen (current: Dermatologikum Hamburg, Prof. Steinkraus und Partner), G&#xF6;ttingen, Germany </aff>
        <aff id="Aff16"><label>16</label>Osnabr&#xFC;ck, Germany </aff>
        <aff id="Aff17"><label>17</label>Oldenburg, Germany </aff>
        <aff id="Aff18"><label>18</label>Abteilung Psychosomatik und Psychotherapie, Medizinische Hochschule Hannover, Hannover, Germany </aff>
        <aff id="Aff19"><label>19</label>Mahlow, Germany </aff>
        <aff id="Aff20"><label>20</label>Buchholz, Germany </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>12</day>
        <month>5</month>
        <year>2007</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>6</month>
        <year>2007</year>
      </pub-date>
      <volume>299</volume>
      <issue>3</issue>
      <fpage>111</fpage>
      <lpage>138</lpage>
      <history>
        <date date-type="received">
          <day>13</day>
          <month>2</month>
          <year>2007</year>
        </date>
        <date date-type="accepted">
          <day>14</day>
          <month>2</month>
          <year>2007</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Springer-Verlag 2007</copyright-statement>
      </permissions>
      <abstract>
        <p>Psoriasis vulgaris is a common and chronic inflammatory skin disease which has the potential to significantly reduce the quality of life in severely affected patients. The incidence of psoriasis in Western industrialized countries ranges from 1.5 to 2%. Despite the large variety of treatment options available, patient surveys have revealed insufficient satisfaction with the efficacy of available treatments and a high rate of medication non-compliance. To optimize the treatment of psoriasis in Germany, the Deutsche Dermatologische Gesellschaft and the Berufsverband Deutscher Dermatologen (BVDD) have initiated a project to develop evidence-based guidelines for the management of psoriasis. The guidelines focus on induction therapy in cases of mild, moderate, and severe plaque-type psoriasis in adults. The short version of the guidelines reported here consist of a series of therapeutic recommendations that are based on a systematic literature search and subsequent discussion with experts in the field; they have been approved by a team of dermatology experts. In addition to the therapeutic recommendations provided in this short version, the full version of the guidelines includes information on contraindications, adverse events, drug interactions, practicality, and costs as well as detailed information on how best to apply the treatments described (for full version, please see Nast et al., JDDG, Suppl 2:S1&#x2013;S126, <xref ref-type="bibr" rid="CR149">2006</xref>; or <ext-link ext-link-type="uri" xlink:href="http://www.psoriasis-leitlinie.de">http://www.psoriasis-leitlinie.de</ext-link>).</p>
      </abstract>
      <kwd-group>
        <title>Keywords</title>
        <kwd>Evidence-based guidelines</kwd>
        <kwd>Psoriasis vulgaris</kwd>
        <kwd>Treatment</kwd>
      </kwd-group>
      <custom-meta-wrap>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; Springer-Verlag 2007</meta-value>
        </custom-meta>
      </custom-meta-wrap>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1" sec-type="introduction">
      <title>
        <bold>Introduction</bold>
      </title>
      <p>The Deutsche Dermatologische Gesellschaft (DDG) and the Berufsverband Deutscher Dermatologen (BVDD) have initiated a project to develop evidence-based guidelines for the treatment of plaque psoriasis. The full version of the Guidelines has been published in the Journal der Deutschen Dermatologischen Gesellschaft (JDDG 2006 Suppl 2) and is available at <ext-link ext-link-type="uri" xlink:href="http://www.psoriasis-leitlinie.de">http://www.psoriasis-leitlinie.de</ext-link> [<xref ref-type="bibr" rid="CR149">149</xref>]. This article summarizes the key points of the Guidelines.</p>
      <sec id="Sec2">
        <title>
          <bold>Background</bold>
        </title>
        <p>Psoriasis vulgaris is a common and chronic inflammatory skin disease which has the potential to significantly reduce the quality of life in severely affected patients. The incidence of psoriasis in Western industrialized countries is 1.5&#x2013;2% [<xref ref-type="bibr" rid="CR2">2</xref>]. Studies on the impairment of life quality have shown that, depending on the severity of the disease, a significant burden may exist in the form of a disability or psychosocial stigmatization [<xref ref-type="bibr" rid="CR3">3</xref>]. Patient surveys have shown that the mental and physical impairment associated with psoriasis is comparable to that of other significant chronic conditions, such as type 2 diabetes or chronic respiratory diseases [<xref ref-type="bibr" rid="CR4">4</xref>].</p>
        <p>Patient surveys have shown that only 25% of psoriasis patients are highly satisfied with the outcome of their treatment, another 50% indicate moderate satisfaction, and approximately 20% report low treatment satisfaction [<xref ref-type="bibr" rid="CR5">5</xref>]. In addition, there is a high non-compliance rate in the intake of medication of up to 40% [<xref ref-type="bibr" rid="CR1">1</xref>].</p>
        <p>Experience has shown that treatment selection for patients with psoriasis vulgaris is more commonly based on traditional concepts than on evidence-based data on the efficacy of various therapeutic options. In addition, it appears that systemic therapies are occasionally not applied in situations where they are needed due to the increased effort involved in monitoring the patients for unwanted side effects and possible interactions with other drugs.</p>
      </sec>
      <sec id="Sec3">
        <title>
          <bold>Goal of the Guidelines</bold>
        </title>
        <p>The overall objective of the Guidelines is to provide dermatologists in clinics and private practice with an accepted and evidence-based decision-making tool for the selection and implementation of a suitable and efficacious treatment for patients with psoriasis vulgaris. The focus of the Guidelines is on the induction therapy of mild, moderate, and severe plaque-type psoriasis in adults.<list list-type="order"><list-item><p>Physicians&#x2019; personal experiences and traditional therapeutic concepts should be supplemented and, if necessary, replaced by an evidence-based assessment of the efficacy of individual therapies in psoriasis vulgaris.</p></list-item><list-item><p>The guidelines provide in-depth explanations of the available systemic and topical treatments for psoriasis, including the different photo- and photochemical therapies, and provide detailed descriptions of the administration and safety aspects.</p></list-item><list-item><p>By providing background information on the profile of the available drugs, including efficacy, safety, and aspects of practicality and costs, the Guidelines should facilitate the process of selecting an appropriate treatment for each individual patient. This should help increase compliance and optimize the benefit/risk ratio of psoriasis therapies.</p></list-item></list></p>
      </sec>
    </sec>
    <sec id="Sec4" sec-type="methods">
      <title>
        <bold>Methods</bold>
      </title>
      <p>A detailed description of the methodology employed in developing the Guidelines can be found in the Method Report on the Guidelines (<ext-link ext-link-type="uri" xlink:href="http://www.psoriasis-leitlinie.de">http://www.psoriasis-leitlinie.de</ext-link>).</p>
      <sec id="Sec5">
        <title>
          <bold>Basis of data</bold>
        </title>
        <p>A systematic search of the literature was carried out in May 2005 with the objective of assessing the effectiveness of individual therapeutic options. This search yielded 6,224 publications of which 142 studies fulfilled the inclusion criteria for the Guidelines (see Box&#xA0;1) and were therefore included in the assessment of the effectiveness of the relevant treatment. Various other aspects were evaluated on the basis of information presented in available literature, without a systematic analysis, and the years of personal experience of the experts.
<graphic position="anchor" xlink:href="403_2007_744_Figa_HTML" id="MO1"/></p>
      </sec>
      <sec id="Sec6">
        <title>
          <bold>Evidence assessment</bold>
        </title>
        <p>The efficacy and effectiveness of each intervention was evaluated using evidence-based criteria.</p>
        <p>The methodological quality of each individual study was assessed using the following grades of evidence (GE):<def-list><def-item><term>A<sub>1</sub></term><def><p>Meta-analysis that includes at least one randomized study with grade A<sub>2</sub> evidence. In addition, the results of the different studies included in the meta-analysis must be consistent with one another.</p></def></def-item><def-item><term>A<sub>2</sub></term><def><p>A high-quality (e.g. sample-size calculation, flow chart, intention-to-treat (ITT) analysis, sufficient size) randomized, double-blind comparative clinical study.</p></def></def-item><def-item><term>B</term><def><p>Randomized clinical study of lesser quality or other comparative study (non-randomized, cohort, or case-control study).</p></def></def-item><def-item><term>C</term><def><p>Non-comparative study.</p></def></def-item><def-item><term>D</term><def><p>Expert opinion.</p></def></def-item></def-list>Individual interventions (i.e., as monotherapy) were rated according to the following levels of evidence (LE):<list list-type="order"><list-item><p>Intervention is supported by studies with grade A<sub>1 </sub>evidence or studies with grade A<sub>2</sub> evidence whose results are predominantly consistent with one another.</p></list-item><list-item><p>Intervention is supported by studies with grade A<sub>2</sub> evidence or studies with grade B evidence whose results are predominantly consistent with one another.</p></list-item><list-item><p>Intervention is supported by studies with grade B evidence or studies with grade C evidence whose results are predominantly consistent with one another.</p></list-item><list-item><p>Little or no systematic empirical evidence</p></list-item></list><graphic position="anchor" xlink:href="403_2007_744_Figb_HTML" id="MO2"/></p>
      </sec>
      <sec id="Sec7">
        <title>
          <bold>Therapeutic recommendation</bold>
        </title>
        <p>A distinct rating of the therapeutic options or a strict clinical algorithm cannot be defined for the treatment of psoriasis vulgaris. The criteria for selecting a particular therapy are complex. The decision for a specific treatment should be based on the profile of the available drugs and the characteristics of a given patient. The decision for or against a therapy remains a case-by-case decision. These Guidelines provide a reasonable form of assistance in deciding on a suitable therapy and are an instrument for optimizing the required therapeutic process.</p>
        <p>The recommendations formulated in the text are supported graphically in selected key recommendations by the following indications of the <bold>strength of the therapeutic recommendation</bold>:<def-list><def-item><term>&#x2191;&#x2191;</term><def><p>Measure is highly recommended</p></def></def-item><def-item><term>&#x2191;</term><def><p>Measure is recommended</p></def></def-item><def-item><term>&#x2192;</term><def><p>Neutral</p></def></def-item><def-item><term>&#x2193;</term><def><p>Measure is not recommended</p></def></def-item><def-item><term>&#x2193;&#x2193;</term><def><p>Measure is highly inadvisable</p></def></def-item></def-list>The strength of the recommendation reflects both a treatment&#x2019;s efficacy and the level of evidence supporting it as well as aspects of safety, practicality, and the cost/benefit ratio. A consensus on the strength of the recommendation was reached during the Consensus Conference.</p>
      </sec>
    </sec>
    <sec id="Sec8" sec-type="results">
      <title>
        <bold>Results</bold>
      </title>
      <p>Therapeutic options are named and discussed in alphabetical order.</p>
      <sec id="Sec9">
        <title>
          <bold>Therapeutic strategies</bold>
        </title>
        <fig position="anchor" id="Fig1">
          <label>Fig.&#xA0;1</label>
          <caption>
            <p>Overview of the therapeutic options evaluated for chronic plaque psoriasis (the therapeutic options are listed alphabetically and do not represent a ranking)</p>
          </caption>
          <graphic position="anchor" xlink:href="403_2007_744_Fig1_HTML" id="MO44"/>
        </fig>
      </sec>
      <sec id="Sec10">
        <title>
          <bold>Evaluation of topical and systemic therapies in tabular form</bold>
        </title>
        <p>These tables are intended to provide a rough orientation for evaluating the therapeutic options. Cumulative calculations of the individual aspects for the overall evaluation of the therapeutic options are not possible and cannot be drawn upon for the final analysis of a therapeutic option. The product assessment for each individual patient may deviate greatly. A direct comparison between systemic and topical therapies is not possible because of the different severity of the psoriasis lesions of patients treated with topical or systemic treatments. The evaluations reported here were made on the basis of data extracted from the literature and expert opinions.</p>
        <p>For further details refer to the Methods Report at www.psoriasis-leitlinie.de</p>
        <sec id="Sec11">
          <title>
            <italic>Topical monotherapy</italic>
          </title>
          <p>
            <graphic position="anchor" xlink:href="403_2007_744_Figc_HTML" id="MO3"/>
          </p>
        </sec>
        <sec id="Sec12">
          <title>
            <italic>Phototherapy and systemic monotherapy</italic>
          </title>
          <p>
            <graphic position="anchor" xlink:href="403_2007_744_Figd_HTML" id="MO4"/>
          </p>
          <p>(a) <italic>Efficacy</italic> The evaluation of the efficacy column reflects the percentage of patients who achieved a reduction in the baseline Psoriasis Area and Severity Index (PASI) of &#x2265;75%. 
<table-wrap id="Taba"><table frame="hsides" rules="groups"><thead><tr><th align="left">Scale</th><th align="left">Systemic therapy</th><th align="left">Topical therapy</th></tr></thead><tbody><tr><td align="left">++++</td><td align="left">Approx. 90%</td><td align="left">Approx. 60%</td></tr><tr><td align="left">+++</td><td align="left">Approx. 70%</td><td align="left">Approx. 45%</td></tr><tr><td align="left">++</td><td align="left">Approx. 50%</td><td align="left">Approx. 30%</td></tr><tr><td align="left">+</td><td align="left">Approx. 30%</td><td align="left">Approx. 15%</td></tr><tr><td align="left">+/&#x2212;</td><td align="left">Approx. 10%</td><td align="left">Approx. 5%</td></tr><tr><td align="left">&#x2013;</td><td align="left">Not defined</td><td align="left">Not defined</td></tr></tbody></table></table-wrap></p>
          <p>The evidence level applies only to the estimate of efficacy.</p>
          <p>(b) <italic>Safety/tolerance in induction therapy or maintenance therapy </italic>This refers to the risk of occurrence of severe adverse drug reactions or the probability of adverse drug reactions that would result in the discontinuation of therapy.</p>
          <p>(c) <italic>Practicality (Patient)</italic> This evaluation analyzes the effort involved in handling and administrating the treatment regimen by the patient.</p>
          <p>(d) <italic>Practicality (Physician)</italic> This aspect considers the amount of work (documentation, explanation, monitoring), personnel and equipment needs, time for physician/patient interaction, remuneration of therapeutic measures, invoicing difficulties/risk of recourse claims from the health insurance companies.</p>
          <p>(e) <italic>Cost/benefit </italic>Consideration of the costs of an induction therapy or a maintenance therapy.</p>
          <p>The evaluations of safety/tolerance in induction therapy or maintenance therapy as well as practicality for the physician or patient and the cost/benefit were performed using a scale ranging from poor (&#x2013;) to good (++++). The gradation between these two extremes was made based on expert opinion and unsystematic literature search. A level of evidence was not given for these evaluations since no systematic literature review was performed.</p>
        </sec>
      </sec>
      <sec id="Sec13">
        <title>
          <bold>Evaluation of topical therapies</bold>
        </title>
        <sec id="Sec14">
          <title>
            <italic>Calcineurin inhibitors</italic>
          </title>
          <p>
            <table-wrap id="Tab1">
              <label>Table&#xA0;1</label>
              <caption>
                <p>Tabular summary</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th align="left" colspan="2">Calcineurin inhibitors</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td align="left" colspan="2">First approved in Germany</td>
                  </tr>
                  <tr>
                    <td align="left">&#xA0;Pimecrolimus (Elidel<sup>&#xAE;</sup>)</td>
                    <td align="left">2002 (Atopic dermatitis, not approved for psoriasis vulgaris)</td>
                  </tr>
                  <tr>
                    <td align="left">&#xA0;Tacrolimus (Protopic<sup>&#xAE;</sup>)</td>
                    <td align="left">2002 (Atopic dermatitis, not approved for psoriasis vulgaris)</td>
                  </tr>
                  <tr>
                    <td align="left">Recommended initial dosage</td>
                    <td align="left">Pimecrolimus cream: 1&#xD7; to 2&#xD7; daily<break/>Tacrolimus: 1&#xD7; to 2&#xD7; daily (application on the face: Begin with 0.03% salve; increase later dosage to 0.1% salve)</td>
                  </tr>
                  <tr>
                    <td align="left">Recommended maintenance dosage</td>
                    <td align="left">Individual therapeutic adjustment</td>
                  </tr>
                  <tr>
                    <td align="left">Expected beginning of clinical effect</td>
                    <td align="left">After approximately 2&#xA0;weeks</td>
                  </tr>
                  <tr>
                    <td align="left">Response rate</td>
                    <td align="left">No data available</td>
                  </tr>
                  <tr>
                    <td align="left">Important contraindications</td>
                    <td align="left">Pregnancy and nursing (due to lack of experience) skin infections, immune suppression</td>
                  </tr>
                  <tr>
                    <td align="left">Important adverse drug reactions (ADRs)</td>
                    <td align="left">Burning sensation on skin, skin infections</td>
                  </tr>
                  <tr>
                    <td align="left">Important drug interactions</td>
                    <td align="left">None known</td>
                  </tr>
                  <tr>
                    <td align="left">Other</td>
                    <td align="left">
                      <italic>Cave: Do not combine with phototherapy! Photoprotection!</italic>
                    </td>
                  </tr>
                </tbody>
              </table>
            </table-wrap>
          </p>
          <p>
            <graphic position="anchor" xlink:href="403_2007_744_Fige_HTML" id="MO5"/>
          </p>
          <p>
            <graphic position="anchor" xlink:href="403_2007_744_Figf_HTML" id="MO6"/>
          </p>
        </sec>
        <sec id="Sec15">
          <title>
            <italic>Corticosteroids</italic>
          </title>
          <p>
            <table-wrap id="Tab2">
              <label>Table&#xA0;2</label>
              <caption>
                <p>Tabular summary</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th align="left" colspan="2">Corticosteroids</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td align="left">First approved in Germany</td>
                    <td align="left">1956 (Psoriasis vulgaris)</td>
                  </tr>
                  <tr>
                    <td align="left">Recommended control parameters</td>
                    <td align="left">None</td>
                  </tr>
                  <tr>
                    <td align="left">Recommended initial dosage</td>
                    <td align="left">One to two times daily</td>
                  </tr>
                  <tr>
                    <td align="left">Recommended maintenance dosage</td>
                    <td align="left">Gradual reduction following onset of effect</td>
                  </tr>
                  <tr>
                    <td align="left">Expected beginning of clinical effect</td>
                    <td align="left">After 1&#x2013;2&#xA0;weeks</td>
                  </tr>
                  <tr>
                    <td align="left">Response rate</td>
                    <td align="left">Betamethasone dipropionate, two times daily: marked improvement or clearance of the skin lesions in 46&#x2013;56% patients after 4&#xA0;weeks (LE&#xA0;1)</td>
                  </tr>
                  <tr>
                    <td align="left">Important contraindications</td>
                    <td align="left">Skin infections, rosacea, perioral dermatitis</td>
                  </tr>
                  <tr>
                    <td align="left">Important ADRs</td>
                    <td align="left">Skin infections, perioral dermatitis, skin atrophy, hypertrichosis, striae</td>
                  </tr>
                  <tr>
                    <td align="left">Important drug interactions</td>
                    <td align="left">None</td>
                  </tr>
                  <tr>
                    <td align="left">Other</td>
                    <td align="left">&#x2013;</td>
                  </tr>
                </tbody>
              </table>
            </table-wrap>
          </p>
          <p>
            <graphic position="anchor" xlink:href="403_2007_744_Figg_HTML" id="MO7"/>
          </p>
          <p>
            <graphic position="anchor" xlink:href="403_2007_744_Figh_HTML" id="MO8"/>
          </p>
        </sec>
        <sec id="Sec16">
          <title>
            <italic>Coal tar</italic>
          </title>
          <p>
            <table-wrap id="Tab3">
              <label>Table&#xA0;3</label>
              <caption>
                <p>Tabular summary</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th align="left" colspan="2">Coal tar</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td align="left">First approved in Germany</td>
                    <td align="left">Listed active ingredient since 2000 (DAC on page 170), historical application, various tar-containing externals are licensed as drugs, application of tar as anti-psoriatic following publication by Goeckermann in 1925</td>
                  </tr>
                  <tr>
                    <td align="left">Recommended control parameters</td>
                    <td align="left">After long-term application/application on large areas: if needed clinical controls for potential development of skin carcinoma</td>
                  </tr>
                  <tr>
                    <td align="left">Recommended initial dosage</td>
                    <td align="left">5&#x2013;20% salve preparations or gels for local therapy, 1&#xD7; daily</td>
                  </tr>
                  <tr>
                    <td align="left">Recommended maintenance dosage</td>
                    <td align="left">No long-term application (max. 4&#xA0;weeks, DAC 2000)</td>
                  </tr>
                  <tr>
                    <td align="left">Expected beginning of clinical effect</td>
                    <td align="left">After 4&#x2013;8&#xA0;weeks, efficacy improves in combination with UV application</td>
                  </tr>
                  <tr>
                    <td align="left">Response rate</td>
                    <td align="left">There is insufficient data available on the response rate as a monotherapy (LE 4)</td>
                  </tr>
                  <tr>
                    <td align="left">Important contraindications</td>
                    <td align="left">Pregnancy and nursing</td>
                  </tr>
                  <tr>
                    <td align="left">Important ADRs</td>
                    <td align="left">Color, odor, carcinogenic risk, phototoxicity&#x2014;which is part of the desired effect</td>
                  </tr>
                  <tr>
                    <td align="left">Important drug interactions</td>
                    <td align="left">Not known with topical use</td>
                  </tr>
                  <tr>
                    <td align="left">Other</td>
                    <td align="left">DAC 2000 (on page 170), Hazardous Goods Directive Appendix 4 No. 13</td>
                  </tr>
                </tbody>
              </table>
            </table-wrap>
          </p>
          <p>
            <graphic position="anchor" xlink:href="403_2007_744_Figi_HTML" id="MO9"/>
          </p>
          <p>
            <graphic position="anchor" xlink:href="403_2007_744_Figj_HTML" id="MO10"/>
          </p>
        </sec>
        <sec id="Sec17">
          <title>
            <italic>Dithranol</italic>
          </title>
          <p>
            <table-wrap id="Tab4">
              <label>Table&#xA0;4</label>
              <caption>
                <p>Tabular summary</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th align="left" colspan="2">Dithranol</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td align="left" colspan="2">First approved in Germany</td>
                  </tr>
                  <tr>
                    <td align="left">Psoralon</td>
                    <td align="left">1983 (Psoriasis vulgaris)</td>
                  </tr>
                  <tr>
                    <td align="left">Psoradexan</td>
                    <td align="left">1994 (Psoriasis vulgaris)</td>
                  </tr>
                  <tr>
                    <td align="left">Micanol</td>
                    <td align="left">1997 (Psoriasis vulgaris)</td>
                  </tr>
                  <tr>
                    <td align="left">Recommended control parameters</td>
                    <td align="left">Intensity of irritation</td>
                  </tr>
                  <tr>
                    <td align="left">Recommended initial dosage</td>
                    <td align="left">Begin with 0.5% preparation for long-term therapy or 1% for short-contact therapy, then increase if tolerated</td>
                  </tr>
                  <tr>
                    <td align="left">Recommended maintenance dosage</td>
                    <td align="left">Not recommended for maintenance therapy </td>
                  </tr>
                  <tr>
                    <td align="left">Expected beginning of clinical effect</td>
                    <td align="left">After 2&#x2013;3&#xA0;weeks</td>
                  </tr>
                  <tr>
                    <td align="left">Response rate </td>
                    <td align="left">Marked improvement or clearance of skin lesions in 30&#x2013;50% of the patients (LE 2)</td>
                  </tr>
                  <tr>
                    <td align="left">Important contraindications</td>
                    <td align="left">Acute, erythrodermic forms of psoriasis vulgaris; pustular psoriasis</td>
                  </tr>
                  <tr>
                    <td align="left">Important ADRs</td>
                    <td align="left">Burning and reddening of the skin in &gt;10%</td>
                  </tr>
                  <tr>
                    <td align="left">Important drug interactions</td>
                    <td align="left">&#x2013;</td>
                  </tr>
                  <tr>
                    <td align="left">Other</td>
                    <td align="left">&#x2013;</td>
                  </tr>
                </tbody>
              </table>
            </table-wrap>
          </p>
          <p>
            <graphic position="anchor" xlink:href="403_2007_744_Figk_HTML" id="MO11"/>
          </p>
          <p>
            <graphic position="anchor" xlink:href="403_2007_744_Figl_HTML" id="MO12"/>
          </p>
        </sec>
        <sec id="Sec18">
          <title>
            <italic>Tazarotene</italic>
          </title>
          <p>
            <table-wrap id="Tab5">
              <label>Table&#xA0;5</label>
              <caption>
                <p>Tabular summary</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th align="left" colspan="2">Tazarotene</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td align="left">First approved in Germany</td>
                    <td align="left">1997 (psoriasis vulgaris)</td>
                  </tr>
                  <tr>
                    <td align="left">Recommended control parameters</td>
                    <td align="left">Check development of skin irritations</td>
                  </tr>
                  <tr>
                    <td align="left">Recommended initial dosage</td>
                    <td align="left">Begin with one treatment daily of tazarotene gel 0.05% in the evening for approximately 1&#x2013;2&#xA0;weeks</td>
                  </tr>
                  <tr>
                    <td align="left">Recommended maintenance dosage</td>
                    <td align="left">If necessary continue for 1&#x2013;2&#xA0;weeks with tazarotene gel 0.1%</td>
                  </tr>
                  <tr>
                    <td align="left">Expected beginning of clinical effect</td>
                    <td align="left">After 1&#x2013;2&#xA0;weeks</td>
                  </tr>
                  <tr>
                    <td align="left">Response rate</td>
                    <td align="left">After 12&#xA0;weeks therapy with 0.1% tazarotene gel improved findings of at least 50% in approximately 50% of the patients (LE 2)</td>
                  </tr>
                  <tr>
                    <td align="left">Important contraindications</td>
                    <td align="left">Pregnancy, nursing</td>
                  </tr>
                  <tr>
                    <td align="left">Important ADRs</td>
                    <td align="left">Pruritus, burning sensation of skin, erythema, irritation</td>
                  </tr>
                  <tr>
                    <td align="left">Important drug interactions</td>
                    <td align="left">Avoid concomitant use of preparations with irritating and drying properties </td>
                  </tr>
                  <tr>
                    <td align="left">Other</td>
                    <td align="left">&#x2013;</td>
                  </tr>
                </tbody>
              </table>
            </table-wrap>
          </p>
          <p>
            <graphic position="anchor" xlink:href="403_2007_744_Figm_HTML" id="MO13"/>
          </p>
          <p>
            <graphic position="anchor" xlink:href="403_2007_744_Fign_HTML" id="MO14"/>
          </p>
        </sec>
        <sec id="Sec19">
          <title>Vitamin D<sub>3</sub> and analogues</title>
          <p>
            <table-wrap id="Tab6">
              <label>Table&#xA0;6</label>
              <caption>
                <p>Tabular summary</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th align="left" colspan="2">Vitamin D<sub>3</sub> and analogues</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td align="left" colspan="2">First approved in Germany</td>
                  </tr>
                  <tr>
                    <td align="left">&#xA0;Calcipotriol</td>
                    <td align="left">1992 (Psoriasis vulgaris)</td>
                  </tr>
                  <tr>
                    <td align="left">&#xA0;Tacalcitol</td>
                    <td align="left">1994 (Psoriasis vulgaris)</td>
                  </tr>
                  <tr>
                    <td align="left">&#xA0;Calcitriol</td>
                    <td align="left">1999 (Psoriasis vulgaris)</td>
                  </tr>
                  <tr>
                    <td align="left">&#xA0;Calcipotriol/Betamethasone </td>
                    <td align="left">2002 (Psoriasis vulgaris)</td>
                  </tr>
                  <tr>
                    <td align="left">Recommended control parameters</td>
                    <td align="left">Monitor for skin irritations </td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="3">Recommended initial dosage</td>
                    <td align="left">Calcipotriol: 1&#xD7; to 2&#xD7; daily to affected locations, up to a maximum of 30% of the body surface</td>
                  </tr>
                  <tr>
                    <td align="left">Tacalcitol: 1&#xD7; daily to affected locations, up to a maximum of 20% of the body surface</td>
                  </tr>
                  <tr>
                    <td align="left">Calcitriol: 2&#xD7; daily to affected locations, up to a maximum of 35% of the body surface</td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="3">Recommended maintenance dosage</td>
                    <td align="left">Calcipotriol: 1&#xD7; to 2&#xD7; daily, up to 100&#xA0;g/week for up to 1&#xA0;year</td>
                  </tr>
                  <tr>
                    <td align="left">Tacalcitol: 1&#xD7; daily for 8&#xA0;weeks, for up to 18&#xA0;months, on a maximum of 15% of the body surface with up to 3.5&#xA0;g daily</td>
                  </tr>
                  <tr>
                    <td align="left">Calcitriol: insufficient experience with the application for more than 6&#xA0;weeks </td>
                  </tr>
                  <tr>
                    <td align="left">Expected beginning of clinical effect</td>
                    <td align="left">After 1&#x2013;2&#xA0;weeks</td>
                  </tr>
                  <tr>
                    <td align="left">Response rate </td>
                    <td align="left">Between 30 and 50% of the patients demonstrated a marked improvement or clearance of the lesions after 4&#x2013;6&#xA0;weeks (LE 1)</td>
                  </tr>
                  <tr>
                    <td align="left">Important contraindications</td>
                    <td align="left">Diseases with abnormal calcium metabolism, severe liver and renal diseases</td>
                  </tr>
                  <tr>
                    <td align="left">Important ADRs</td>
                    <td align="left">Skin irritation (reddening, itching, burning)</td>
                  </tr>
                  <tr>
                    <td align="left">Important drug interactions</td>
                    <td align="left">Drugs which elevate the calcium levels, (e.g. thiazide diuretics), no concomitant application of topical salicylic acid preparations (inactivation)</td>
                  </tr>
                  <tr>
                    <td align="left">Other</td>
                    <td align="left">Exposure to UV light results in inactivation of the vitamin D<sub>3</sub>-analogues</td>
                  </tr>
                </tbody>
              </table>
            </table-wrap>
          </p>
          <p>
            <graphic position="anchor" xlink:href="403_2007_744_Figo_HTML" id="MO15"/>
          </p>
          <p>
            <graphic position="anchor" xlink:href="403_2007_744_Figp_HTML" id="MO16"/>
          </p>
        </sec>
      </sec>
      <sec id="Sec20">
        <title>
          <bold>Phototherapy</bold>
        </title>
        <p>
          <table-wrap id="Tab7">
            <label>Table&#xA0;7</label>
            <caption>
              <p>Tabular summary</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th align="left" colspan="2">Phototherapy</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td align="left">First approved in Germany</td>
                  <td align="left">Clinical experience, depending on the modality for &gt;50&#xA0;years</td>
                </tr>
                <tr>
                  <td align="left">Recommended control parameters</td>
                  <td align="left">Regular skin inspection (UV erythema)</td>
                </tr>
                <tr>
                  <td align="left" rowspan="4">Recommended initial dosage</td>
                  <td align="left">Individual dose depends on skin type; options:</td>
                </tr>
                <tr>
                  <td align="left">&#x2022; UVB: 70% of minimum erythema dose (MED)</td>
                </tr>
                <tr>
                  <td align="left">&#x2022; Oral PUVA (photochemotherapy): 75% of the minimum phototoxic dose (MPD)</td>
                </tr>
                <tr>
                  <td align="left">&#x2022; Bath/cream PUVA: 20<bold>&#x2013;</bold>30% of MPD</td>
                </tr>
                <tr>
                  <td align="left">Recommended maintenance dosage</td>
                  <td align="left">Increase according to degree of UV erythema</td>
                </tr>
                <tr>
                  <td align="left">Expected beginning of clinical effect</td>
                  <td align="left">After 1&#x2013;2&#xA0;weeks </td>
                </tr>
                <tr>
                  <td align="left">Response rate</td>
                  <td align="left">In &gt;75% of the patients PASI, 75 after 4&#x2013;6&#xA0;weeks (LE 2)</td>
                </tr>
                <tr>
                  <td align="left">Important contraindications</td>
                  <td align="left">Photo-dermatoses/photosensitive diseases, skin malignancies, immunosuppression<break/>Only PUVA: pregnancy and nursing</td>
                </tr>
                <tr>
                  <td align="left">Important ADRs</td>
                  <td align="left">Erythema, itching, blistering, malignancies<break/>Only oral PUVA: nausea </td>
                </tr>
                <tr>
                  <td align="left">Important drug interactions</td>
                  <td align="left">Drugs causing phototoxicity or photoallergy</td>
                </tr>
                <tr>
                  <td align="left">Other</td>
                  <td align="left">Combination with topical preparations acts synergistically, PUVA may not be combined with cyclosporine</td>
                </tr>
              </tbody>
            </table>
          </table-wrap>
        </p>
        <p>
          <graphic position="anchor" xlink:href="403_2007_744_Figq_HTML" id="MO17"/>
        </p>
        <p>
          <graphic position="anchor" xlink:href="403_2007_744_Figr_HTML" id="MO18"/>
        </p>
      </sec>
      <sec id="Sec21">
        <title>
          <bold>Evaluation of systemic therapies</bold>
        </title>
        <sec id="Sec34">
          <title>
            <italic>Efalizumab</italic>
          </title>
          <p>
            <table-wrap id="Tab8">
              <label>Table&#xA0;8</label>
              <caption>
                <p>Tabular summary</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th align="left" colspan="2">Efalizumab</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td align="left">First approved in Germany</td>
                    <td align="left">September 2004 (psoriasis vulgaris)</td>
                  </tr>
                  <tr>
                    <td align="left">Recommended control parameters</td>
                    <td align="left">Prior to therapy exclusion of significant infections, complete blood count, liver values </td>
                  </tr>
                  <tr>
                    <td align="left">Recommended initial dosage</td>
                    <td align="left">0.7&#xA0;mg/kg body weight (BW) per week</td>
                  </tr>
                  <tr>
                    <td align="left">Recommended maintenance dosage</td>
                    <td align="left">1&#xA0;mg/kg BW per week</td>
                  </tr>
                  <tr>
                    <td align="left">Expected beginning of clinical effect </td>
                    <td align="left">After 4&#x2013;8&#xA0;weeks</td>
                  </tr>
                  <tr>
                    <td align="left">Response rate</td>
                    <td align="left">PASI 75 for approximately 30% of the patients after 12&#xA0;weeks (LE 1)</td>
                  </tr>
                  <tr>
                    <td align="left">Important contraindications (limited selection)</td>
                    <td align="left">Chronic or acute infections, pregnancy, malignant diseases, immune deficiencies, no vaccinations before or during treatment</td>
                  </tr>
                  <tr>
                    <td align="left">Important ADRs (limited selection)</td>
                    <td align="left">Flu-like injection reactions, leukocytosis and lymphocytosis, rebound, exacerbation and arthralgia, thrombocytopenia</td>
                  </tr>
                  <tr>
                    <td align="left">Important drug interactions</td>
                    <td align="left">Not known </td>
                  </tr>
                  <tr>
                    <td align="left">Other</td>
                    <td align="left">Stop therapy due to the risk of exacerbation and rebound if a PASI reduction of 50% is not achieved after 12&#xA0;weeks</td>
                  </tr>
                </tbody>
              </table>
            </table-wrap>
          </p>
          <p>
            <graphic position="anchor" xlink:href="403_2007_744_Figs_HTML" id="MO19"/>
          </p>
          <p>
            <table-wrap id="Tab9">
              <label>Table&#xA0;9</label>
              <caption>
                <p>Laboratory controls during treatment with efalizumab</p>
              </caption>
              <graphic xlink:href="403_2007_744_Tab1_HTML" id="MO45"/>
              <table-wrap-foot>
                <p><sup>a</sup>Hb (hemoglobin), HCT (hematocrit), erythrocytes, leukocytes, differential blood count, platelets</p>
                <p><sup>b</sup>ALT alanine aminotransferase, AST aspartate aminotransferase</p>
              </table-wrap-foot>
            </table-wrap>
          </p>
          <p>
            <graphic position="anchor" xlink:href="403_2007_744_Figt_HTML" id="MO20"/>
          </p>
          <p>
            <graphic position="anchor" xlink:href="403_2007_744_Figu_HTML" id="MO21"/>
          </p>
          <sec id="Sec24">
            <title>
              <italic>Etanercept</italic>
            </title>
            <p>
              <table-wrap id="Tab10">
                <label>Table&#xA0;10</label>
                <caption>
                  <p>Tabular summary</p>
                </caption>
                <table frame="hsides" rules="groups">
                  <thead>
                    <tr>
                      <th align="left" colspan="2">Etanercept</th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td align="left">First approved in Germany</td>
                      <td align="left">2002 (Psoriasis arthritis )/2004 (psoriasis vulgaris)</td>
                    </tr>
                    <tr>
                      <td align="left">Recommended control parameters</td>
                      <td align="left">Prior to therapy exclusion of tuberculosis, complete blood count, liver and renal values, urinanalysis </td>
                    </tr>
                    <tr>
                      <td align="left">Recommended initial dosage</td>
                      <td align="left">Twice 25&#xA0;mg per week or 2&#xD7; 50&#xA0;mg/week</td>
                    </tr>
                    <tr>
                      <td align="left">Recommended maintenance dosage</td>
                      <td align="left">Twice 25&#xA0;mg per week</td>
                    </tr>
                    <tr>
                      <td align="left">Expected beginning of clinical effect </td>
                      <td align="left">After 4&#x2013;8&#xA0;weeks, at the latest after 12&#xA0;weeks</td>
                    </tr>
                    <tr>
                      <td align="left">Response rate</td>
                      <td align="left">PASI 75 in 34% (2&#xA0;&#xD7;&#xA0;25&#xA0;mg) or 49% (2&#xA0;&#xD7;&#xA0;50&#xA0;mg) of the patients at the end of the induction phase (12&#xA0;weeks) (LE 1)</td>
                    </tr>
                    <tr>
                      <td align="left">Important contraindications (limited selection)</td>
                      <td align="left">Infections, pregnancy, nursing, heart failure NYHA III&#x2013;IV</td>
                    </tr>
                    <tr>
                      <td align="left">Important ADRs (limited selection)</td>
                      <td align="left">Local reactions, infections </td>
                    </tr>
                    <tr>
                      <td align="left">Important drug interactions (limited selection)</td>
                      <td align="left">Anakinra (IL-1 receptor antagonist)</td>
                    </tr>
                    <tr>
                      <td align="left">Other</td>
                      <td align="left">&#x2013;</td>
                    </tr>
                  </tbody>
                </table>
              </table-wrap>
            </p>
            <p>
              <graphic position="anchor" xlink:href="403_2007_744_Figv_HTML" id="MO22"/>
            </p>
            <p>
              <table-wrap id="Tab11">
                <label>Table&#xA0;11</label>
                <caption>
                  <p>Laboratory controls during treatment with etanercept</p>
                </caption>
                <graphic xlink:href="403_2007_744_Tab2_HTML" id="MO46"/>
              </table-wrap>
            </p>
            <p>
              <graphic position="anchor" xlink:href="403_2007_744_Figw_HTML" id="MO23"/>
            </p>
          </sec>
          <sec id="Sec25">
            <title>
              <italic>Infliximab</italic>
            </title>
            <p>
              <table-wrap id="Tab12">
                <label>Table&#xA0;12</label>
                <caption>
                  <p>Tabular summary</p>
                </caption>
                <table frame="hsides" rules="groups">
                  <thead>
                    <tr>
                      <th align="left" colspan="2">Infliximab</th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td align="left">First approved in Germany</td>
                      <td align="left">2004 (Psoriasis arthritis)/2005 (psoriasis vulgaris)</td>
                    </tr>
                    <tr>
                      <td align="left">Recommended control parameters</td>
                      <td align="left">Prior to therapy exclusion of tuberculosis, during therapy: leukocyte and platelet counts, liver value controls, signs of clinical infection</td>
                    </tr>
                    <tr>
                      <td align="left">Recommended initial dosage</td>
                      <td align="left">5&#xA0;mg/kg BW at week 0, 2, 6</td>
                    </tr>
                    <tr>
                      <td align="left">Recommended maintenance dosage</td>
                      <td align="left">5&#xA0;mg/kg BW in dosage intervals of 8&#xA0;weeks</td>
                    </tr>
                    <tr>
                      <td align="left">Expected beginning of clinical effect </td>
                      <td align="left">After 1&#x2013;2&#xA0;weeks</td>
                    </tr>
                    <tr>
                      <td align="left">Response rate</td>
                      <td align="left">PASI 75 in &#x2265;80% of the patients with moderate to severe psoriasis vulgaris (LE 1)</td>
                    </tr>
                    <tr>
                      <td align="left">Important contraindications (limited selection)</td>
                      <td align="left">Acute or chronic infections, tuberculosis, cardiac failure NYHA III&#x2013;IV, pregnancy and nursing</td>
                    </tr>
                    <tr>
                      <td align="left">Important ADRs (limited selection)</td>
                      <td align="left">Infusion reactions, severe infections, progression of heart failure NYHA III&#x2013;IV, very rare liver failure, autoimmune phenomena</td>
                    </tr>
                    <tr>
                      <td align="left">Important drug interactions (limited selection)</td>
                      <td align="left">Anakinra (IL-1 receptor antagonist)</td>
                    </tr>
                    <tr>
                      <td align="left">Other</td>
                      <td align="left">&#x2013;</td>
                    </tr>
                  </tbody>
                </table>
              </table-wrap>
            </p>
            <p>
              <graphic position="anchor" xlink:href="403_2007_744_Figx_HTML" id="MO25"/>
            </p>
            <p>
              <table-wrap id="Tab13">
                <label>Table&#xA0;13</label>
                <caption>
                  <p>Laboratory controls during treatment with infliximab</p>
                </caption>
                <graphic xlink:href="403_2007_744_Tab3_HTML" id="MO47"/>
                <table-wrap-foot>
                  <p><sup>a</sup>Hb, HCT, erythrocytes, leukocytes, differential blood count, platelets</p>
                </table-wrap-foot>
              </table-wrap>
            </p>
            <p>
              <graphic position="anchor" xlink:href="403_2007_744_Figy_HTML" id="MO26"/>
            </p>
          </sec>
        </sec>
        <sec id="Sec26">
          <title>
            <italic>Cyclosporine</italic>
          </title>
          <p>
            <table-wrap id="Tab14">
              <label>Table&#xA0;14</label>
              <caption>
                <p>Tabular summary</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th align="left" colspan="2">Cyclosporine</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td align="left" rowspan="2">First approved in Germany</td>
                    <td align="left">1983 (Transplantation medicine)</td>
                  </tr>
                  <tr>
                    <td align="left">1993 (Psoriasis vulgaris)</td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="6">Recommended control parameters</td>
                    <td align="left">Interview/examination: </td>
                  </tr>
                  <tr>
                    <td align="left">&#x2022; Status of skin and mucous membranes</td>
                  </tr>
                  <tr>
                    <td align="left">&#x2022; Signs of infection</td>
                  </tr>
                  <tr>
                    <td align="left">&#x2022; Neurological, gastrointestinal symptoms</td>
                  </tr>
                  <tr>
                    <td align="left">&#x2022; Blood pressure</td>
                  </tr>
                  <tr>
                    <td align="left">Laboratory controls: see Table&#xA0;<xref rid="Tab14" ref-type="table">14</xref></td>
                  </tr>
                  <tr>
                    <td align="left">Recommended initial dosage</td>
                    <td align="left">2.5&#x2013;3 (max. 5) mg/kg BW</td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="3">Recommended maintenance dosage</td>
                    <td align="left">Interval therapy (between 8 and 16 weeks) with dosage reduction at the end of the induction therapy (e.g., 0.5 mg/kg BW every 14&#xA0;days) or</td>
                  </tr>
                  <tr>
                    <td align="left">Continuous long-term therapy with dosage reduction (e.g. by 50&#xA0;mg every 4&#xA0;weeks after week 12) and a dosage increase by 50&#xA0;mg with relapse</td>
                  </tr>
                  <tr>
                    <td align="left">Maximum total duration of therapy: 2&#xA0;years</td>
                  </tr>
                  <tr>
                    <td align="left">Expected beginning of clinical effect</td>
                    <td align="left">After approximately 4&#xA0;weeks</td>
                  </tr>
                  <tr>
                    <td align="left">Response rate</td>
                    <td align="left">Dose-dependent: after 8&#x2013;16&#xA0;weeks with 3&#xA0;mg/kg BW; PASI 90 in approximately 30&#x2013;50% of patient and PASI 75 in approximately 50&#x2013;70% of patients (LE 1)</td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="4">Important contraindications (limited selection)</td>
                    <td align="left"><bold>Absolute</bold>:</td>
                  </tr>
                  <tr>
                    <td align="left">Reduced renal function, insufficiently controlled arterial hypertension, uncontrolled infections, relevant malignancies (current or previous, in particular hematologic diseases and cutaneous malignancies with the exception of basal cell carcinoma)</td>
                  </tr>
                  <tr>
                    <td align="left">
                      <bold>Relative:</bold>
                    </td>
                  </tr>
                  <tr>
                    <td align="left">Relevant hepatic dysfunction, pregnancy and nursing, concomitant use of substance which interacts with cyclosporine, concomitant UV-therapy or prior PUVA-pre-therapy with cumulative dosage &gt;1000 J/cm&#xB2;, concomitant application of other immunosuppressives, retinoids or long-term prior-therapy with methotrexate (MTX)</td>
                  </tr>
                  <tr>
                    <td align="left">Important ADRs (limited selection)</td>
                    <td align="left">Renal failure, increase of blood pressure, liver failure, nausea, anorexia, vomiting, diarrhea, hypertrichosis, gingival hyperplasia, tremor, weariness, parasthesia, hyperlipidemia</td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="7">Important drug interactions (limited selection)</td>
                    <td align="left">Increase of the cyclosporine level (CYP3A inhibition) through:</td>
                  </tr>
                  <tr>
                    <td align="left">Allopurinol, calcium antagonists, amiodarone, antibiotics (macrolides, clarithromycin, josamycin, ponsinomycin, pristinamycin, doxycycline, gentamicin, tobramycin, ticarcillin, quinolones), ketoconazole, oral contraceptives, methylprednisolone (high dosages), ranitidine, cimetidine, grapefruit juice</td>
                  </tr>
                  <tr>
                    <td align="left">Decrease of the cyclosporine level (CYP3A induction) through: Carbamazepine, phenytoin, barbiturates, metamizole, St. John&#x2019;s wort </td>
                  </tr>
                  <tr>
                    <td align="left">Possible reinforcement of nephrotoxic adverse drug reactions through: Aminoglycosides, amphotericin B, ciprofloxacin, acyclovir, non-steroidal antiphlogistics</td>
                  </tr>
                  <tr>
                    <td align="left">Specific interactions:</td>
                  </tr>
                  <tr>
                    <td align="left">Potassium-saving substances: increased risk of hyperpotassemia</td>
                  </tr>
                  <tr>
                    <td align="left">Reduced clearance of: Digoxin, colchicine, prednisolone, HMG-CoA reductase inhibitors (e.g. lovastatin), diclofenac</td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="3">Other</td>
                    <td align="left">Increased risk of lympho-proliferative diseases in transplant patients. Increased risk of squamous cell carcinoma in psoriasis patients following excessive phototherapy.</td>
                  </tr>
                  <tr>
                    <td align="left">Only moderately effective in and not approved for psoriatic arthritis </td>
                  </tr>
                  <tr>
                    <td align="left">Also used successfully in the therapy of chronic-inflammatory diseases in children</td>
                  </tr>
                </tbody>
              </table>
            </table-wrap>
          </p>
          <p>
            <graphic position="anchor" xlink:href="403_2007_744_Figz_HTML" id="MO28"/>
          </p>
          <p>
            <table-wrap id="Tab15">
              <label>Table&#xA0;15</label>
              <caption>
                <p>Laboratory controls during treatment with cyclosporine</p>
              </caption>
              <graphic xlink:href="403_2007_744_Tab4_HTML" id="MO48"/>
              <table-wrap-foot>
                <p><sup>a</sup>Erythrocytes, leukocytes, platelets</p>
                <p><sup>b</sup>ALT, AST, AP (alkaline phosphatase), &#x3B3;GT (gamma glutamyl transpeptidase), bilirubin</p>
                <p><sup>c</sup>Sodium, potassium</p>
                <p><sup>d</sup>Recommended twice (fasting) and week-2 and 0</p>
                <p><sup>e</sup>Only with indication (e.g. muscle cramps)</p>
              </table-wrap-foot>
            </table-wrap>
          </p>
          <p>
            <graphic position="anchor" xlink:href="403_2007_744_Figaa_HTML" id="MO29"/>
          </p>
        </sec>
        <sec id="Sec27">
          <title>
            <italic>Fumaric acid esters</italic>
          </title>
          <p>
            <table-wrap id="Tab16">
              <label>Table&#xA0;16</label>
              <caption>
                <p>Tabular summary</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th align="left" colspan="2">Fumaric acid esters</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td align="left">First approved in Germany</td>
                    <td align="left">1995 (Psoriasis vulgaris) </td>
                  </tr>
                  <tr>
                    <td align="left">Recommended control parameters</td>
                    <td align="left">Serum creatinine, transaminases/&#x3B3;GT, complete blood count including differential blood count, urinanalysis</td>
                  </tr>
                  <tr>
                    <td align="left">Recommended initial dosage</td>
                    <td align="left">According to recommended dosage regimen see Table&#xA0;<xref rid="Tab17" ref-type="table">17</xref></td>
                  </tr>
                  <tr>
                    <td align="left">Recommended maintenance dosage</td>
                    <td align="left">Individually adapted dosage</td>
                  </tr>
                  <tr>
                    <td align="left">Expected beginning of clinical effect</td>
                    <td align="left">After approximately 6 weeks</td>
                  </tr>
                  <tr>
                    <td align="left">Response rate</td>
                    <td align="left">PASI 75 in 50&#x2013;70% of the patients at the end of the induction phase after 16 weeks (LE 2)</td>
                  </tr>
                  <tr>
                    <td align="left">Important contraindications (limited selection)</td>
                    <td align="left">Chronic diseases of the gastrointestinal tract and/or the kidneys and chronic diseases, which are accompanied by an impairment of the leukocyte count or functions, malignant diseases, pregnancy and nursing </td>
                  </tr>
                  <tr>
                    <td align="left">Important ADRs (limited selection)</td>
                    <td align="left">Gastrointestinal complaints, flush, lymphopenia, eosinophilia</td>
                  </tr>
                  <tr>
                    <td align="left">Important drug interactions</td>
                    <td align="left">None known</td>
                  </tr>
                  <tr>
                    <td align="left">Other</td>
                    <td align="left">&#x2013;</td>
                  </tr>
                </tbody>
              </table>
            </table-wrap>
          </p>
          <p>
            <table-wrap id="Tab17">
              <label>Table&#xA0;17</label>
              <caption>
                <p>Dosage regimen for Fumaderm therapy</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th align="left"/>
                    <th align="left">Fumaderm initial</th>
                    <th align="left">Fumaderm</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td align="left">Week 1</td>
                    <td align="left">1-0-0</td>
                    <td align="left"/>
                  </tr>
                  <tr>
                    <td align="left">Week 2</td>
                    <td align="left">1-0-1</td>
                    <td align="left"/>
                  </tr>
                  <tr>
                    <td align="left">Week 3</td>
                    <td align="left">1-1-1</td>
                    <td align="left"/>
                  </tr>
                  <tr>
                    <td align="left">Week 4</td>
                    <td align="left"/>
                    <td align="left">1-0-0</td>
                  </tr>
                  <tr>
                    <td align="left">Week 5</td>
                    <td align="left"/>
                    <td align="left">1-0-1</td>
                  </tr>
                  <tr>
                    <td align="left">Week 6</td>
                    <td align="left"/>
                    <td align="left">1-1-1</td>
                  </tr>
                  <tr>
                    <td align="left">Week 7</td>
                    <td align="left"/>
                    <td align="left">2-1-1</td>
                  </tr>
                  <tr>
                    <td align="left">Week 8</td>
                    <td align="left"/>
                    <td align="left">2-1-2</td>
                  </tr>
                  <tr>
                    <td align="left">Week 9</td>
                    <td align="left"/>
                    <td align="left">2-2-2</td>
                  </tr>
                </tbody>
              </table>
            </table-wrap>
          </p>
          <p>
            <graphic position="anchor" xlink:href="403_2007_744_Figab_HTML" id="MO31"/>
          </p>
          <p>
            <table-wrap id="Tab18">
              <label>Table&#xA0;18</label>
              <caption>
                <p>Laboratory controls during treatment with fumaric acid esters</p>
              </caption>
              <graphic xlink:href="403_2007_744_Tab5_HTML" id="MO49"/>
              <table-wrap-foot>
                <p><sup>a</sup>Leukocytes, platelets, erythrocytes, differential blood count</p>
              </table-wrap-foot>
            </table-wrap>
          </p>
          <p>
            <graphic position="anchor" xlink:href="403_2007_744_Figac_HTML" id="MO32"/>
          </p>
        </sec>
        <sec id="Sec28">
          <title>
            <italic>Methotrexate</italic>
          </title>
          <p>
            <table-wrap id="Tab19">
              <label>Table&#xA0;19</label>
              <caption>
                <p>Tabular summary</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th align="left" colspan="2">Methotrexate</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td align="left" colspan="2">First approved in Germany</td>
                  </tr>
                  <tr>
                    <td align="left">&#xA0;Lantarel<sup>&#xAE;</sup></td>
                    <td align="left">1991 (Psoriasis vulgaris)</td>
                  </tr>
                  <tr>
                    <td align="left">&#xA0;Metex<sup>&#xAE;</sup> 7.5/10&#xA0;mg</td>
                    <td align="left">1992 (Psoriasis vulgaris)</td>
                  </tr>
                  <tr>
                    <td align="left">&#xA0;Metex<sup>&#xAE;</sup> 2.5&#xA0;mg</td>
                    <td align="left">2004 (Psoriasis vulgaris)</td>
                  </tr>
                  <tr>
                    <td align="left">Recommended control parameters</td>
                    <td align="left">Complete blood count (Hb, HCT, differential blood count, platelets), renal function (serum creatinine, urea, urine sediment), liver values (serum transaminases), III-procollagen amino terminal propeptides </td>
                  </tr>
                  <tr>
                    <td align="left">Recommended initial dosage</td>
                    <td align="left">5&#x2013;15&#xA0;mg per week</td>
                  </tr>
                  <tr>
                    <td align="left">Recommended maintenance dosage</td>
                    <td align="left">5&#x2013;22.5&#xA0;mg per week depending on effect</td>
                  </tr>
                  <tr>
                    <td align="left">Expected beginning of clinical effect</td>
                    <td align="left">After 4&#x2013;8&#xA0;weeks</td>
                  </tr>
                  <tr>
                    <td align="left">Response rate</td>
                    <td align="left">PASI 75 in approximately 60% of the patients at the end of the induction phase of 16&#xA0;weeks (LE 3)</td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="4">Important contraindications (limited selection)</td>
                    <td align="left"><bold>Absolute contraindications</bold>:</td>
                  </tr>
                  <tr>
                    <td align="left">Desire to have children (for both men and women), pregnancy and nursing, inadequate contraception, drug consumption, alcoholism, known sensitivity to active ingredient methotrexate (e.g. pulmonary toxicity), bone marrow dysfunction, severe liver disease, severe infections, immunodeficiency, active peptic ulcers, hematologic changes (leucopenia, thrombocytopenia, anemia), renal failure</td>
                  </tr>
                  <tr>
                    <td align="left"><bold>Relative contraindications</bold>:</td>
                  </tr>
                  <tr>
                    <td align="left">Kidney disorders, liver disorders, history of arsenic consumption , chronic congestive cardio-myopathy, adiposity, old age, diabetes mellitus, history of hepatitis, lack of patient compliance, ulcerative colitis, diarrhea, NSAID use, gastritis</td>
                  </tr>
                  <tr>
                    <td align="left">Important ADRs (limited selection)</td>
                    <td align="left">Liver fibrosis/cirrhosis, pneumonia/alveolitis, bone marrow depression, renal damage, alopecia (reversible), nausea, weariness, vomiting, elevated transaminases, infection, gastrointestinal ulcerations, nephrotoxicity</td>
                  </tr>
                  <tr>
                    <td align="left">Important drug interactions (limited selection)</td>
                    <td align="left">Cyclosporine, salicylates, sulfonamides, probenecide, penicillin, colchicin, NSAIDs (naproxene, ibuprofene, etc.), ethanol, co-trimoxazole, pyrimethamine, chloramphenicol, sulfonamides, prostaglandin synthesis inhibitors, cytostatics, probenecide, barbiturates, phenytoin, retinoids, sulfonamides, sulfonylurea, tetracyclines, co-trimoxazol, chloramphenicol, dipyridamole, retinoids, ethanol, leflunomide</td>
                  </tr>
                  <tr>
                    <td align="left">Other</td>
                    <td align="left">Consistent avoidance of alcohol, X-ray of the lungs prior to beginning therapy </td>
                  </tr>
                </tbody>
              </table>
            </table-wrap>
          </p>
          <p>
            <graphic position="anchor" xlink:href="403_2007_744_Figad_HTML" id="MO34"/>
          </p>
          <p>
            <table-wrap id="Tab20">
              <label>Table&#xA0;20</label>
              <caption>
                <p>Laboratory controls during treatment with MTX [<xref ref-type="bibr" rid="CR137">137</xref>]</p>
              </caption>
              <graphic xlink:href="403_2007_744_Tab6_HTML" id="MO50"/>
              <table-wrap-foot>
                <p><sup>a</sup>Hb, HCT, erythrocytes, leukocytes, differential blood count, platelets</p>
                <p><sup>b</sup>ALT, AST, AP, &#x3B3;GT, albumin, bilirubin, lactate dehydrogenase (LDH)</p>
                <p><sup>c</sup>Liver biopsy instead of a liver sonography in risk groups</p>
              </table-wrap-foot>
            </table-wrap>
          </p>
          <p>
            <graphic position="anchor" xlink:href="403_2007_744_Figae_HTML" id="MO35"/>
          </p>
        </sec>
        <sec id="Sec29">
          <title>
            <italic>Retinoids</italic>
          </title>
          <p>
            <table-wrap id="Tab21">
              <label>Table&#xA0;21</label>
              <caption>
                <p>Tabular summary</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th align="left" colspan="2">Acitretin</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td align="left">First approved in Germany</td>
                    <td align="left">1992 (Psoriasis vulgaris)</td>
                  </tr>
                  <tr>
                    <td align="left">Recommended control parameters</td>
                    <td align="left">Erythrocyte sedimentation rate (ESR), complete blood count, liver values, renal values, blood lipid values, pregnancy test, x-ray control of the bones in case of long-term therapy</td>
                  </tr>
                  <tr>
                    <td align="left">Recommended initial dosage</td>
                    <td align="left">0.3&#x2013;0.5&#xA0;mg/kg BW per day for approximately 4&#xA0;weeks, then 0.5&#x2013;0.8&#xA0;mg/kg BW</td>
                  </tr>
                  <tr>
                    <td align="left">Recommended maintenance dosage</td>
                    <td align="left">Individual dosaging dependent on the results and tolerance </td>
                  </tr>
                  <tr>
                    <td align="left">Expected beginning of clinical effect</td>
                    <td align="left">After 4&#x2013;8&#xA0;weeks</td>
                  </tr>
                  <tr>
                    <td align="left">Response rate</td>
                    <td align="left">Widely variable and dose-dependent, no definite statement possible, partial remission (PASI 75) in 25&#x2013;75% of the patients (30&#x2013;40&#xA0;mg per day) (LE 3) in studies</td>
                  </tr>
                  <tr>
                    <td align="left">Important contraindications (limited selection)</td>
                    <td align="left">Renal and liver damage, desire to have children in female patients of child-bearing age, pregnancy, nursing, alcohol abuse, manifest diabetes mellitus, wearing of contact lenses, history of pancreatitis, hyperlipidemia requiring drug treatment</td>
                  </tr>
                  <tr>
                    <td align="left">Important ADRs (limited selection)</td>
                    <td align="left">Hypervitaminosis A (e.g., cheilitis, xerosis, nose-bleeding, alopecia, increased skin fragility) </td>
                  </tr>
                  <tr>
                    <td align="left">Important drug interactions (limited selection)</td>
                    <td align="left">Phenytoin, tetracyclines, methotrexate, alcohol, mini-pill</td>
                  </tr>
                  <tr>
                    <td align="left">Other</td>
                    <td align="left">Contraception up to 2&#xA0;years after discontinuation in female patients of child-bearing age</td>
                  </tr>
                </tbody>
              </table>
            </table-wrap>
          </p>
          <p>
            <graphic position="anchor" xlink:href="403_2007_744_Figaf_HTML" id="MO37"/>
          </p>
          <p><sup>a</sup>Double contraception is recommended (e.g., condom&#xA0;+&#xA0;pill; IUD/Nuva-Ring&#xA0;+&#xA0;pill; cave: no low-dosed progesterone preparations/mini-pills) during and up to 2&#xA0;years after the end of therapy; effectiveness is reduced by acitretin</p>
          <p>
            <table-wrap id="Tab22">
              <label>Table&#xA0;22</label>
              <caption>
                <p>Laboratory controls during treatment with Acitretin</p>
              </caption>
              <graphic xlink:href="403_2007_744_Tab7_HTML" id="MO51"/>
              <table-wrap-foot>
                <p><sup>a</sup>Hb, HCT, leukocytes, platelets</p>
                <p><sup>b</sup>Preferably assayed twice (week-2 and 0); HDL, high-density lipidoprotein</p>
              </table-wrap-foot>
            </table-wrap>
          </p>
          <p>
            <graphic position="anchor" xlink:href="403_2007_744_Figag_HTML" id="MO38"/>
          </p>
        </sec>
      </sec>
      <sec id="Sec30">
        <title>
          <bold>Other therapies</bold>
        </title>
        <sec id="Sec31">
          <title>
            <italic>Climate/balneotherapy</italic>
          </title>
          <p>
            <table-wrap id="Tab23">
              <label>Table&#xA0;23</label>
              <caption>
                <p>Tabular summary</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th align="left" colspan="2">Climate/balneotherapy</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td align="left">First approved in Germany</td>
                    <td align="left">Clinical experience with balneotherapy has existed for more than 200&#xA0;years </td>
                  </tr>
                  <tr>
                    <td align="left">Recommended control parameters</td>
                    <td align="left">Regular skin inspection</td>
                  </tr>
                  <tr>
                    <td align="left">Recommended initial dosage</td>
                    <td align="left">Therapy regimens vary depending on the institution/location</td>
                  </tr>
                  <tr>
                    <td align="left">Recommended maintenance dosage</td>
                    <td align="left">Therapy regimens vary depending on the institution/location</td>
                  </tr>
                  <tr>
                    <td align="left">Expected beginning of clinical effect</td>
                    <td align="left">Varies greatly</td>
                  </tr>
                  <tr>
                    <td align="left">Response rate</td>
                    <td align="left">Varies greatly (LE 4)</td>
                  </tr>
                  <tr>
                    <td align="left">Important contraindications</td>
                    <td align="left">Dependent on modality selected</td>
                  </tr>
                  <tr>
                    <td align="left">Important ADRs</td>
                    <td align="left">Dependent on modality selected</td>
                  </tr>
                  <tr>
                    <td align="left">Important drug interactions</td>
                    <td align="left">Not applicable</td>
                  </tr>
                  <tr>
                    <td align="left">Other</td>
                    <td align="left">Balneotherapy and climate therapy are frequently combined</td>
                  </tr>
                </tbody>
              </table>
            </table-wrap>
          </p>
          <p>
            <graphic position="anchor" xlink:href="403_2007_744_Figah_HTML" id="MO40"/>
          </p>
          <p>
            <graphic position="anchor" xlink:href="403_2007_744_Figai_HTML" id="MO41"/>
          </p>
        </sec>
        <sec id="Sec32">
          <title>
            <italic>Psychosocial therapy</italic>
          </title>
          <p>
            <graphic position="anchor" xlink:href="403_2007_744_Figaj_HTML" id="MO42"/>
          </p>
          <p>
            <graphic position="anchor" xlink:href="403_2007_744_Figak_HTML" id="MO43"/>
          </p>
        </sec>
      </sec>
    </sec>
    <sec id="Sec33">
      <title>Notes on the use of the Guidelines</title>
      <p>The presentation of the therapies deliberately focused on those aspects deemed particularly relevant by a panel of experts. Aspects which are not of specific importance for a certain intervention, but which are part of the physician&#x2019;s general obligations to the patient, such as the investigation of intolerance and allergies toward certain drugs or the exclusion of contraindications, are not individually listed, but it is nevertheless taken for granted that these are part of the physician&#x2019;s duty to provide care.</p>
      <p>It is recommended that each and every user carefully reads and follows the product information and compare it with the recommendations in the Guidelines on dosaging, contraindications, and drug interactions for completeness and currentness. Every dose or application is administered at the user&#x2019;s own risk. The authors and the publishers kindly request that users inform them of any inaccuracies that they might notice. The users are requested to keep themselves constantly informed of any new findings subsequent to the publication of the Guidelines.</p>
    </sec>
  </body>
  <back>
    <ack>
      <p>The guidelines were generated upon request by the Deutsche Dermatologische Gesellschaft (DDG) and the Berufsverband Deutscher Dermatologen (BVDD). The project was supported by the &#x2018;F&#xF6;rderverein der Deutschen Dermatologischen Gesellschaft&#x2019;, the funding body of the DDG. </p>
      <p><bold>Conflicts of interests</bold> All authors have filled in specific forms to declare their conflicts of interests. These forms are available online under www.psoriasis-leitlinie.de. The experts involved in drawing up these guidelines received no payments for their work other than travel expenses.</p>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Richards</surname>
              <given-names>HL</given-names>
            </name>
            <name>
              <surname>Fortune</surname>
              <given-names>DG</given-names>
            </name>
            <name>
              <surname>O&#x2019;Sullivan</surname>
              <given-names>TM</given-names>
            </name>
            <name>
              <surname>Main</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Griffiths</surname>
              <given-names>CE</given-names>
            </name>
          </person-group>
          <article-title>Patients with psoriasis and their compliance with medication</article-title>
          <source>J Am Acad Dermatol</source>
          <year>1999</year>
          <volume>41</volume>
          <issue>4</issue>
          <fpage>581</fpage>
          <lpage>583</lpage>
        </citation>
        <citation citation-type="display-unstructured">Richards HL, Fortune DG, O&#x2019;Sullivan TM, Main CJ, Griffiths CE (1999) Patients with psoriasis and their compliance with medication. J Am Acad Dermatol 41(4):581&#x2013;583 <pub-id pub-id-type="pmid">10495380</pub-id></citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nevitt</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>Hutchinson</surname>
              <given-names>PE</given-names>
            </name>
          </person-group>
          <article-title>Psoriasis in the community: prevalence, severity and patients&#x2019; beliefs and attitudes towards the disease</article-title>
          <source>Br J Dermatol</source>
          <year>1996</year>
          <volume>135</volume>
          <issue>4</issue>
          <fpage>533</fpage>
          <lpage>537</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1365-2133.1996.d01-1035.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Nevitt GJ, Hutchinson PE (1996) Psoriasis in the community: prevalence, severity and patients&#x2019; beliefs and attitudes towards the disease. Br J Dermatol 135(4):533&#x2013;537 <pub-id pub-id-type="pmid">8915141</pub-id></citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schmid-Ott</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Malewski</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Kreiselmaier</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Mrowietz</surname>
              <given-names>U</given-names>
            </name>
          </person-group>
          <article-title>Psychosoziale Folgen der Psoriasis&#x2014;eine empirische Studie &#xFC;ber die Krankheitslast bei 3753 Betroffenen</article-title>
          <source>Hautarzt</source>
          <year>2005</year>
          <volume>56</volume>
          <issue>5</issue>
          <fpage>466</fpage>
          <lpage>472</lpage>
          <pub-id pub-id-type="doi">10.1007/s00105-005-0906-9</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Schmid-Ott G, Malewski P, Kreiselmaier I, Mrowietz U (2005) Psychosoziale Folgen der Psoriasis&#x2014;eine empirische Studie &#xFC;ber die Krankheitslast bei 3753 Betroffenen. Hautarzt 56(5):466&#x2013;472 <pub-id pub-id-type="pmid">15711815</pub-id></citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rapp</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Feldman</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Exum</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Fleischer</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Reboussin</surname>
              <given-names>DM</given-names>
            </name>
          </person-group>
          <article-title>Psoriasis causes as much disability as other major medical diseases</article-title>
          <source>J Am Acad Dermatol</source>
          <year>1999</year>
          <volume>41</volume>
          <issue>3 Pt 1</issue>
          <fpage>401</fpage>
          <lpage>407</lpage>
          <pub-id pub-id-type="doi">10.1016/S0190-9622(99)70112-X</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM (1999) Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 41(3 Pt 1): 401&#x2013;407 <pub-id pub-id-type="pmid">10459113</pub-id></citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stern</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Nijsten</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Feldman</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Margolis</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Rolstad</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction</article-title>
          <source>J Invest Dermatol Symp Proc</source>
          <year>2004</year>
          <volume>9</volume>
          <issue>2</issue>
          <fpage>136</fpage>
          <lpage>139</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1087-0024.2003.09102.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T (2004) Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Invest Dermatol Symp Proc 9(2):136&#x2013;139 </citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Carroll</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Clarke</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Camacho</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Balkrishnan</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Feldman</surname>
              <given-names>SR</given-names>
            </name>
          </person-group>
          <article-title>Topical tacrolimus ointment combined with 6% salicylic acid gel for plaque psoriasis treatment</article-title>
          <source>Arch Dermatol</source>
          <year>2005</year>
          <volume>141</volume>
          <issue>1</issue>
          <fpage>43</fpage>
          <lpage>46</lpage>
          <pub-id pub-id-type="doi">10.1001/archderm.141.1.43</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Carroll CL, Clarke J, Camacho F, Balkrishnan R, Feldman SR (2005) Topical tacrolimus ointment combined with 6% salicylic acid gel for plaque psoriasis treatment. Arch Dermatol 141(1):43&#x2013;46 <pub-id pub-id-type="pmid">15655140</pub-id></citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Agarwal</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Saraswat</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kaur</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Katare</surname>
              <given-names>OP</given-names>
            </name>
            <name>
              <surname>Kumar</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>A novel liposomal formulation of dithranol for psoriasis: preliminary results</article-title>
          <source>J Dermatol</source>
          <year>2002</year>
          <volume>29</volume>
          <issue>8</issue>
          <fpage>529</fpage>
          <lpage>532</lpage>
        </citation>
        <citation citation-type="display-unstructured">Agarwal R, Saraswat A, Kaur I, Katare OP, Kumar B (2002) A novel liposomal formulation of dithranol for psoriasis: preliminary results. J Dermatol 29(8):529&#x2013;532 <pub-id pub-id-type="pmid">12227489</pub-id></citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Monastirli</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Georgiou</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Pasmatzi</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Sakkis</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Badavanis</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Drainas</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Sagriotis</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Tsambaos</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Calcipotriol plus short-contact dithranol: a novel topical combination therapy for chronic plaque psoriasis</article-title>
          <source>Skin Pharmacol Appl Skin Physiol</source>
          <year>2002</year>
          <volume>15</volume>
          <issue>4</issue>
          <fpage>246</fpage>
          <lpage>251</lpage>
          <pub-id pub-id-type="doi">10.1159/000065971</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Monastirli A, Georgiou S, Pasmatzi E, Sakkis T, Badavanis G, Drainas D, Sagriotis A, Tsambaos D (2002) Calcipotriol plus short-contact dithranol: a novel topical combination therapy for chronic plaque psoriasis. Skin Pharmacol Appl Skin Physiol 15(4):246&#x2013;251 <pub-id pub-id-type="pmid">12218286</pub-id></citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gerritsen</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Boezeman</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Elbers</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Kerkhof</surname>
              <given-names>PC</given-names>
            </name>
          </person-group>
          <article-title>Dithranol embedded in crystalline monoglycerides combined with phototherapy (UVB): a new approach in the treatment of psoriasis</article-title>
          <source>Skin Pharmacol Appl Skin Physiol</source>
          <year>1998</year>
          <volume>11</volume>
          <issue>3</issue>
          <fpage>133</fpage>
          <lpage>139</lpage>
          <pub-id pub-id-type="doi">10.1159/000029819</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Gerritsen MJ, Boezeman JB, Elbers ME, van de Kerkhof PC (1998) Dithranol embedded in crystalline monoglycerides combined with phototherapy (UVB): a new approach in the treatment of psoriasis. Skin Pharmacol Appl Skin Physiol 11(3):133&#x2013;139 <pub-id pub-id-type="pmid">9745140</pub-id></citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Prins</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Swinkels</surname>
              <given-names>OQ</given-names>
            </name>
            <name>
              <surname>Kerkhof</surname>
              <given-names>PC</given-names>
            </name>
            <name>
              <surname>Valk</surname>
              <given-names>PG</given-names>
            </name>
          </person-group>
          <article-title>The impact of the frequency of short contact dithranol treatment</article-title>
          <source>Eur J Dermatol</source>
          <year>2001</year>
          <volume>11</volume>
          <issue>3</issue>
          <fpage>214</fpage>
          <lpage>218</lpage>
        </citation>
        <citation citation-type="display-unstructured">Prins M, Swinkels OQ, Van de Kerkhof PC, Van der Valk PG (2001) The impact of the frequency of short contact dithranol treatment. Eur J Dermatol 11(3):214&#x2013;218 <pub-id pub-id-type="pmid">11358727</pub-id></citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thune</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Brolund</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Short- and long-contact therapy using a new dithranol formulation in individually adjusted dosages in the management of psoriasis</article-title>
          <source>Acta Derm Venereol Suppl</source>
          <year>1992</year>
          <volume>172</volume>
          <fpage>28</fpage>
          <lpage>29</lpage>
        </citation>
        <citation citation-type="display-unstructured">Thune P, Brolund L (1992) Short- and long-contact therapy using a new dithranol formulation in individually adjusted dosages in the management of psoriasis. Acta Derm Venereol Suppl 172:28&#x2013;29 </citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mare</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Calis</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Hartog</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Erp</surname>
              <given-names>PE</given-names>
            </name>
            <name>
              <surname>Kerkhof</surname>
              <given-names>PC</given-names>
            </name>
          </person-group>
          <article-title>The relevance of salicylic acid in the treatment of plaque psoriasis with dithranol creams</article-title>
          <source>Skin Pharmacol</source>
          <year>1988</year>
          <volume>1</volume>
          <issue>4</issue>
          <fpage>259</fpage>
          <lpage>264</lpage>
        </citation>
        <citation citation-type="display-unstructured">De Mare S, Calis N, den Hartog G, van Erp PE, van de Kerkhof PC (1988) The relevance of salicylic acid in the treatment of plaque psoriasis with dithranol creams. Skin Pharmacol 1(4):259&#x2013;264 <pub-id pub-id-type="pmid">2483115</pub-id></citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Prins</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Swinkels</surname>
              <given-names>OQ</given-names>
            </name>
            <name>
              <surname>Bouwhuis</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Gast</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Bouwman-Boer</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Valk</surname>
              <given-names>PG</given-names>
            </name>
            <name>
              <surname>Kerkhof</surname>
              <given-names>PC</given-names>
            </name>
          </person-group>
          <article-title>Dithranol in a cream preparation: disperse or dissolve?</article-title>
          <source>Skin Pharmacol Appl Skin Physiol</source>
          <year>2000</year>
          <volume>13</volume>
          <issue>5</issue>
          <fpage>273</fpage>
          <lpage>279</lpage>
          <pub-id pub-id-type="doi">10.1159/000029933</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Prins M, Swinkels OQ, Bouwhuis S, de Gast MJ, Bouwman-Boer Y, van der Valk PG, van de Kerkhof PC (2000) Dithranol in a cream preparation: disperse or dissolve? Skin Pharmacol Appl Skin Physiol 13(5):273&#x2013;279 <pub-id pub-id-type="pmid">10940817</pub-id></citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hutchinson</surname>
              <given-names>PE</given-names>
            </name>
            <name>
              <surname>Marks</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>White</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>The efficacy, safety and tolerance of calcitriol 3 microg/g ointment in the treatment of plaque psoriasis: a comparison with short-contact dithranol</article-title>
          <source>Dermatology</source>
          <year>2000</year>
          <volume>201</volume>
          <issue>2</issue>
          <fpage>139</fpage>
          <lpage>145</lpage>
          <pub-id pub-id-type="doi">10.1159/000018457</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Hutchinson PE, Marks R, White J (2000) The efficacy, safety and tolerance of calcitriol 3 microg/g ointment in the treatment of plaque psoriasis: a comparison with short-contact dithranol. Dermatology 201(2):139&#x2013;145 <pub-id pub-id-type="pmid">11053917</pub-id></citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <citation citation-type="other">Mahrle G, Schulze HJ (1990) The effect of initial external glucocorticoid administration on cignolin treatment of psoriasis. Z Hautkr 65(3):282, 285&#x2013;287</citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Agrup</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Agdell</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>A comparison between Antraderm stick (0.5% and 1%) and dithranol paste (0.125% and 0.25%) in the treatment of psoriasis</article-title>
          <source>Br J Clin Pract</source>
          <year>1985</year>
          <volume>39</volume>
          <issue>5</issue>
          <fpage>185</fpage>
          <lpage>187</lpage>
        </citation>
        <citation citation-type="display-unstructured">Agrup G, Agdell J (1985) A comparison between Antraderm stick (0.5% and 1%) and dithranol paste (0.125% and 0.25%) in the treatment of psoriasis. Br J Clin Pract 39(5):185&#x2013;187 <pub-id pub-id-type="pmid">3907683</pub-id></citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Swinkels</surname>
              <given-names>OQ</given-names>
            </name>
            <name>
              <surname>Prins</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kucharekova</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Boo</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Gerritsen</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Valk</surname>
              <given-names>PG</given-names>
            </name>
            <name>
              <surname>Kerkhof</surname>
              <given-names>PC</given-names>
            </name>
          </person-group>
          <article-title>Combining lesional short-contact dithranol therapy of psoriasis with a potent topical corticosteroid</article-title>
          <source>Br J Dermatol</source>
          <year>2002</year>
          <volume>146</volume>
          <issue>4</issue>
          <fpage>621</fpage>
          <lpage>626</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1365-2133.2002.04698.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Swinkels OQ, Prins M, Kucharekova M, de Boo T, Gerritsen MJ, van der Valk PG, van de Kerkhof PC (2002) Combining lesional short-contact dithranol therapy of psoriasis with a potent topical corticosteroid. Br J Dermatol 146(4):621&#x2013;626 <pub-id pub-id-type="pmid">11966693</pub-id></citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gottlieb</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Ford</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Spellman</surname>
              <given-names>MC</given-names>
            </name>
          </person-group>
          <article-title>The efficacy and tolerability of clobetasol propionate foam 0.05% in the treatment of mild to moderate plaque-type psoriasis of nonscalp regions</article-title>
          <source>J Cutan Med Surg</source>
          <year>2003</year>
          <volume>7</volume>
          <issue>3</issue>
          <fpage>185</fpage>
          <lpage>192</lpage>
        </citation>
        <citation citation-type="display-unstructured">Gottlieb AB, Ford R, Spellman MC (2003) The efficacy and tolerability of clobetasol propionate foam 0.05% in the treatment of mild to moderate plaque-type psoriasis of nonscalp regions. J Cutan Med Surg 7(3):185&#x2013;192 <pub-id pub-id-type="pmid">12704534</pub-id></citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chuang</surname>
              <given-names>TY</given-names>
            </name>
            <name>
              <surname>Samson</surname>
              <given-names>CR</given-names>
            </name>
          </person-group>
          <article-title>Clinical efficacy and safety of augmented betamethasone dipropionate ointment and diflorasone ointment for psoriasis&#x2014;a multicentre, randomized, double-blinded study</article-title>
          <source>J Dermatol Treat</source>
          <year>1991</year>
          <volume>2</volume>
          <issue>2</issue>
          <fpage>63</fpage>
          <lpage>66</lpage>
        </citation>
        <citation citation-type="display-unstructured">Chuang TY, Samson CR (1991) Clinical efficacy and safety of augmented betamethasone dipropionate ointment and diflorasone ointment for psoriasis&#x2014;a multicentre, randomized, double-blinded study. J Dermatol Treat 2(2):63&#x2013;66 </citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Katz</surname>
              <given-names>HI</given-names>
            </name>
            <name>
              <surname>Tanner</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Cuffie</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Brody</surname>
              <given-names>NI</given-names>
            </name>
            <name>
              <surname>Garcia</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Lowe</surname>
              <given-names>NJ</given-names>
            </name>
            <name>
              <surname>Medansky</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Roth</surname>
              <given-names>HL</given-names>
            </name>
            <name>
              <surname>Shavin</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Swinyer</surname>
              <given-names>LJ</given-names>
            </name>
          </person-group>
          <article-title>A comparison of the efficacy and saftey of the combination mometasone furoate 0,1%/salicylic acid 5% ointment with each of its components in psoriasis</article-title>
          <source>J Dermatol Treat</source>
          <year>1998</year>
          <volume>9</volume>
          <issue>3</issue>
          <fpage>151</fpage>
          <lpage>156</lpage>
        </citation>
        <citation citation-type="display-unstructured">Katz HI, Tanner DJ, Cuffie CA, Brody NI, Garcia CJ, Lowe NJ, Medansky RS, Roth HL, Shavin JS, Swinyer LJ (1998) A comparison of the efficacy and saftey of the combination mometasone furoate 0,1%/salicylic acid 5% ointment with each of its components in psoriasis. J Dermatol Treat 9(3):151&#x2013;156 </citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Koo</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Cuffie</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Tanner</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Bressinck</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Cornell</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>DeVillez</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Edwards</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Breneman</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Piacquadio</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Guzzo</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Monroe</surname>
              <given-names>EW</given-names>
            </name>
          </person-group>
          <article-title>Mometasone furoate 0.1%&#x2013;salicylic acid 5% ointment versus mometasone furoate 0.1% ointment in the treatment of moderate-to-severe psoriasis: a multicenter study</article-title>
          <source>Clin Ther</source>
          <year>1998</year>
          <volume>20</volume>
          <issue>2</issue>
          <fpage>283</fpage>
          <lpage>291</lpage>
          <pub-id pub-id-type="doi">10.1016/S0149-2918(98)80091-X</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Koo J, Cuffie CA, Tanner DJ, Bressinck R, Cornell RC, DeVillez RL, Edwards L, Breneman DL, Piacquadio DJ, Guzzo CA, Monroe EW (1998) Mometasone furoate 0.1%&#x2013;salicylic acid 5% ointment versus mometasone furoate 0.1% ointment in the treatment of moderate-to-severe psoriasis: a multicenter study. Clin Ther 20(2):283&#x2013;291 <pub-id pub-id-type="pmid">9589819</pub-id></citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Camarasa</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Ortonne</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Dubertret</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Calcitriol shows greater persistence of treatment effect than betamethasone dipropionate in topical psoriasis therapy</article-title>
          <source>J Dermatol Treat</source>
          <year>2003</year>
          <volume>14</volume>
          <issue>1</issue>
          <fpage>8</fpage>
          <lpage>13</lpage>
          <pub-id pub-id-type="doi">10.1080/09546630305545</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Camarasa JM, Ortonne JP, Dubertret L (2003) Calcitriol shows greater persistence of treatment effect than betamethasone dipropionate in topical psoriasis therapy. J Dermatol Treat 14(1):8&#x2013;13 </citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Papp</surname>
              <given-names>KA</given-names>
            </name>
            <name>
              <surname>Guenther</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Boyden</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Larsen</surname>
              <given-names>FG</given-names>
            </name>
            <name>
              <surname>Harvima</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Guilhou</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Kaufmann</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Rogers</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kerkhof</surname>
              <given-names>PC</given-names>
            </name>
            <name>
              <surname>Hanssen</surname>
              <given-names>LI</given-names>
            </name>
            <name>
              <surname>Tegner</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Burg</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Talbot</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Chu</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis</article-title>
          <source>J Am Acad Dermatol</source>
          <year>2003</year>
          <volume>48</volume>
          <issue>1</issue>
          <fpage>48</fpage>
          <lpage>54</lpage>
          <pub-id pub-id-type="doi">10.1067/mjd.2003.130</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Papp KA, Guenther L, Boyden B, Larsen FG, Harvima RJ, Guilhou JJ, Kaufmann R, Rogers S, van de Kerkhof PC, Hanssen LI, Tegner E, Burg G, Talbot D, Chu A (2003) Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol 48(1):48&#x2013;54 <pub-id pub-id-type="pmid">12522370</pub-id></citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Douglas</surname>
              <given-names>WS</given-names>
            </name>
            <name>
              <surname>Poulin</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Decroix</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Ortonne</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Mrowietz</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Gulliver</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Krogstad</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Larsen</surname>
              <given-names>FG</given-names>
            </name>
            <name>
              <surname>Iglesias</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Buckley</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Bibby</surname>
              <given-names>AJ</given-names>
            </name>
          </person-group>
          <article-title>A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris</article-title>
          <source>Acta Derm Venereol</source>
          <year>2002</year>
          <volume>82</volume>
          <issue>2</issue>
          <fpage>131</fpage>
          <lpage>135</lpage>
          <pub-id pub-id-type="doi">10.1080/00015550252948194</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Douglas WS, Poulin Y, Decroix J, Ortonne JP, Mrowietz U, Gulliver W, Krogstad AL, Larsen FG, Iglesias L, Buckley C, Bibby AJ (2002) A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Derm Venereol 82(2):131&#x2013;135 <pub-id pub-id-type="pmid">12125943</pub-id></citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kaufmann</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Bibby</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Bissonnette</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Cambazard</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Chu</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Decroix</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Douglas</surname>
              <given-names>WS</given-names>
            </name>
            <name>
              <surname>Lowson</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Mascaro</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Murphy</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>Stymne</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>A new calcipotriol/betamethasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis vulgaris</article-title>
          <source>Dermatology</source>
          <year>2002</year>
          <volume>205</volume>
          <issue>4</issue>
          <fpage>389</fpage>
          <lpage>393</lpage>
          <pub-id pub-id-type="doi">10.1159/000066440</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Kaufmann R, Bibby AJ, Bissonnette R, Cambazard F, Chu AC, Decroix J, Douglas WS, Lowson D, Mascaro JM, Murphy GM, Stymne B (2002) A new calcipotriol/betamethasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis vulgaris. Dermatology 205(4):389&#x2013;393 <pub-id pub-id-type="pmid">12444337</pub-id></citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stein</surname>
              <given-names>LF</given-names>
            </name>
            <name>
              <surname>Sherr</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Solodkina</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Gottlieb</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Chaudhari</surname>
              <given-names>U</given-names>
            </name>
          </person-group>
          <article-title>Betamethasone valerate foam for treatment of nonscalp psoriasis</article-title>
          <source>J Cutan Med Surg</source>
          <year>2001</year>
          <volume>5</volume>
          <issue>4</issue>
          <fpage>303</fpage>
          <lpage>307</lpage>
        </citation>
        <citation citation-type="display-unstructured">Stein LF, Sherr A, Solodkina G, Gottlieb AB, Chaudhari U (2001) Betamethasone valerate foam for treatment of nonscalp psoriasis. J Cutan Med Surg 5(4):303&#x2013;307 <pub-id pub-id-type="pmid">11907840</pub-id></citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Decroix</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Pres</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Tsankov</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Poncet</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Arsonnaud</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Clobetasol propionate lotion in the treatment of moderate to severe plaque-type psoriasis</article-title>
          <source>Cutis</source>
          <year>2004</year>
          <volume>74</volume>
          <issue>3</issue>
          <fpage>201</fpage>
          <lpage>206</lpage>
        </citation>
        <citation citation-type="display-unstructured">Decroix J, Pres H, Tsankov N, Poncet M, Arsonnaud S (2004) Clobetasol propionate lotion in the treatment of moderate to severe plaque-type psoriasis. Cutis 74(3):201&#x2013;206 <pub-id pub-id-type="pmid">15499763</pub-id></citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lebwohl</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Sherer</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Washenik</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Krueger</surname>
              <given-names>GG</given-names>
            </name>
            <name>
              <surname>Menter</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Koo</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Feldman</surname>
              <given-names>SR</given-names>
            </name>
          </person-group>
          <article-title>A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis</article-title>
          <source>Int J Dermatol</source>
          <year>2002</year>
          <volume>41</volume>
          <issue>5</issue>
          <fpage>269</fpage>
          <lpage>274</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1365-4362.2002.01431.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Lebwohl M, Sherer D, Washenik K, Krueger GG, Menter A, Koo J, Feldman SR (2002) A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis. Int J Dermatol 41(5):269&#x2013;274 <pub-id pub-id-type="pmid">12100701</pub-id></citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Peharda</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Gruber</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Prpic</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Kastelan</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Brajac</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>Comparison of mometasone furoate 0.1% ointment and betamethasone dipropionate 0.05% ointment in the treatment of psoriasis vulgaris</article-title>
          <source>Acta Derm Venereol Croat</source>
          <year>2000</year>
          <volume>8</volume>
          <issue>4</issue>
          <fpage>223</fpage>
          <lpage>226</lpage>
        </citation>
        <citation citation-type="display-unstructured">Peharda V, Gruber F, Prpic L, Kastelan M, Brajac I (2000) Comparison of mometasone furoate 0.1% ointment and betamethasone dipropionate 0.05% ointment in the treatment of psoriasis vulgaris. Acta Derm Venereol Croat 8(4):223&#x2013;226 </citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shupack</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Jondreau</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Kenny</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Stiller</surname>
              <given-names>MJ</given-names>
            </name>
          </person-group>
          <article-title>Diflorasone diacetate ointment 0.05% versus betamethasone dipropionate ointment 0.05% in moderate-severe plaque-type psoriasis</article-title>
          <source>Dermatology</source>
          <year>1993</year>
          <volume>186</volume>
          <issue>2</issue>
          <fpage>129</fpage>
          <lpage>132</lpage>
        </citation>
        <citation citation-type="display-unstructured">Shupack JL, Jondreau L, Kenny C, Stiller MJ (1993) Diflorasone diacetate ointment 0.05% versus betamethasone dipropionate ointment 0.05% in moderate-severe plaque-type psoriasis. Dermatology 186(2):129&#x2013;132 <pub-id pub-id-type="pmid">8428041</pub-id></citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Svensson</surname>
              <given-names>ARI</given-names>
            </name>
            <name>
              <surname>Gisslen</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Nordin</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Gios</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>A comperative study of mometasone furoate oinment and betamethasone valerate ointment in patients with Psoriasis vulgaris</article-title>
          <source>Curr Ther Res Clin Exp</source>
          <year>1992</year>
          <volume>52</volume>
          <issue>3</issue>
          <fpage>390</fpage>
          <lpage>396</lpage>
          <pub-id pub-id-type="doi">10.1016/S0011-393X(05)80413-8</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Svensson ARI, Gisslen H, Nordin P, Gios I (1992) A comperative study of mometasone furoate oinment and betamethasone valerate ointment in patients with Psoriasis vulgaris. Curr Ther Res Clin Exp 52(3):390&#x2013;396 </citation>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Weston</surname>
              <given-names>WL</given-names>
            </name>
            <name>
              <surname>Fennessey</surname>
              <given-names>PV</given-names>
            </name>
            <name>
              <surname>Morelli</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Schwab</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Mooney</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Samson</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Huff</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Harrison</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Gotlin</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Comparison of hypothalamus-pituitary-adrenal axis suppression from superpotent topical steroids by standard endocrine function testing and gas chromatographic mass spectrometry</article-title>
          <source>J Invest Dermatol</source>
          <year>1988</year>
          <volume>90</volume>
          <issue>4</issue>
          <fpage>532</fpage>
          <lpage>535</lpage>
          <pub-id pub-id-type="doi">10.1111/1523-1747.ep12461062</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Weston WL, Fennessey PV, Morelli J, Schwab H, Mooney J, Samson C, Huff L, Harrison LM, Gotlin R (1988) Comparison of hypothalamus-pituitary-adrenal axis suppression from superpotent topical steroids by standard endocrine function testing and gas chromatographic mass spectrometry. J Invest Dermatol 90(4):532&#x2013;535 <pub-id pub-id-type="pmid">3351336</pub-id></citation>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Medansky</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Cuffie</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Tanner</surname>
              <given-names>DJ</given-names>
            </name>
          </person-group>
          <article-title>Mometasone furoate 0.1%&#x2013;salicylic acid 5% ointment twice daily versus fluocinonide 0.05% ointment twice daily in the management of patients with psoriasis</article-title>
          <source>Clin Ther</source>
          <year>1997</year>
          <volume>19</volume>
          <issue>4</issue>
          <fpage>701</fpage>
          <lpage>709</lpage>
          <pub-id pub-id-type="doi">10.1016/S0149-2918(97)80094-X</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Medansky RS, Cuffie CA, Tanner DJ (1997) Mometasone furoate 0.1%&#x2013;salicylic acid 5% ointment twice daily versus fluocinonide 0.05% ointment twice daily in the management of patients with psoriasis. Clin Ther 19(4):701&#x2013;709 <pub-id pub-id-type="pmid">9377614</pub-id></citation>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Housman</surname>
              <given-names>TS</given-names>
            </name>
            <name>
              <surname>Keil</surname>
              <given-names>KA</given-names>
            </name>
            <name>
              <surname>Mellen</surname>
              <given-names>BG</given-names>
            </name>
            <name>
              <surname>McCarty</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Fleischer</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Feldman</surname>
              <given-names>SR</given-names>
            </name>
          </person-group>
          <article-title>The use of 0.25% zinc pyrithione spray does not enhance the efficacy of clobetasol propionate 0.05% foam in the treatment of psoriasis</article-title>
          <source>J Am Acad Dermatol</source>
          <year>2003</year>
          <volume>49</volume>
          <issue>1</issue>
          <fpage>79</fpage>
          <lpage>82</lpage>
          <pub-id pub-id-type="doi">10.1067/mjd.2003.417</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Housman TS, Keil KA, Mellen BG, McCarty MA, Fleischer AB Jr, Feldman SR (2003) The use of 0.25% zinc pyrithione spray does not enhance the efficacy of clobetasol propionate 0.05% foam in the treatment of psoriasis. J Am Acad Dermatol 49(1):79&#x2013;82 <pub-id pub-id-type="pmid">12833013</pub-id></citation>
      </ref>
      <ref id="CR35">
        <label>35.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bagatell</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Management of psoriasis: a clinical evaluation of the dermatological patch, Actidermregistered trade mark, over a topical steroid</article-title>
          <source>Adv Ther</source>
          <year>1988</year>
          <volume>5</volume>
          <issue>6</issue>
          <fpage>291</fpage>
          <lpage>296</lpage>
        </citation>
        <citation citation-type="display-unstructured">Bagatell F (1988) Management of psoriasis: a clinical evaluation of the dermatological patch, Actidermregistered trade mark, over a topical steroid. Adv Ther 5(6):291&#x2013;296 </citation>
      </ref>
      <ref id="CR36">
        <label>36.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fabry</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Yawalkar</surname>
              <given-names>SJ</given-names>
            </name>
          </person-group>
          <article-title>A comparative multicentre trial of halometasone ointment and fluocortolone plus fluocortolone caproate ointment in the treatment of psoriasis</article-title>
          <source>J Int Med Res</source>
          <year>1983</year>
          <volume>11</volume>
          <issue>Suppl 1</issue>
          <fpage>26</fpage>
          <lpage>30</lpage>
        </citation>
        <citation citation-type="display-unstructured">Fabry H, Yawalkar SJ (1983) A comparative multicentre trial of halometasone ointment and fluocortolone plus fluocortolone caproate ointment in the treatment of psoriasis. J Int Med Res 11(Suppl 1):26&#x2013;30 <pub-id pub-id-type="pmid">6339289</pub-id></citation>
      </ref>
      <ref id="CR37">
        <label>37.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Belsito</surname>
              <given-names>DV</given-names>
            </name>
            <name>
              <surname>Kechijian</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>The role of tar in Goeckerman therapy</article-title>
          <source>Arch Dermatol</source>
          <year>1982</year>
          <volume>118</volume>
          <issue>5</issue>
          <fpage>319</fpage>
          <lpage>321</lpage>
          <pub-id pub-id-type="doi">10.1001/archderm.118.5.319</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Belsito DV, Kechijian P (1982) The role of tar in Goeckerman therapy. Arch Dermatol 118(5): 319&#x2013;321 <pub-id pub-id-type="pmid">7082024</pub-id></citation>
      </ref>
      <ref id="CR38">
        <label>38.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Diette</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Momtaz</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Stern</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Arndt</surname>
              <given-names>KA</given-names>
            </name>
            <name>
              <surname>Parrish</surname>
              <given-names>JA</given-names>
            </name>
          </person-group>
          <article-title>Role of ultraviolet A in phototherapy for psoriasis</article-title>
          <source>J Am Acad Dermatol</source>
          <year>1984</year>
          <volume>11</volume>
          <issue>3</issue>
          <fpage>441</fpage>
          <lpage>447</lpage>
        </citation>
        <citation citation-type="display-unstructured">Diette KM, Momtaz K, Stern RS, Arndt KA, Parrish JA (1984) Role of ultraviolet A in phototherapy for psoriasis. J Am Acad Dermatol 11(3):441&#x2013;447 <pub-id pub-id-type="pmid">6384291</pub-id></citation>
      </ref>
      <ref id="CR39">
        <label>39.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>LeVine</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Parrish</surname>
              <given-names>JA</given-names>
            </name>
          </person-group>
          <article-title>The effect of topical fluocinonide ointment on phototherapy of psoriasis</article-title>
          <source>J Invest Dermatol</source>
          <year>1982</year>
          <volume>78</volume>
          <issue>2</issue>
          <fpage>157</fpage>
          <lpage>159</lpage>
          <pub-id pub-id-type="doi">10.1111/1523-1747.ep12506317</pub-id>
        </citation>
        <citation citation-type="display-unstructured">LeVine MJ, Parrish JA (1982) The effect of topical fluocinonide ointment on phototherapy of psoriasis. J Invest Dermatol 78(2):157&#x2013;159 <pub-id pub-id-type="pmid">7057051</pub-id></citation>
      </ref>
      <ref id="CR40">
        <label>40.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Frost</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Horwitz</surname>
              <given-names>SN</given-names>
            </name>
            <name>
              <surname>Caputo</surname>
              <given-names>RV</given-names>
            </name>
            <name>
              <surname>Berger</surname>
              <given-names>SM</given-names>
            </name>
          </person-group>
          <article-title>Tar gel-phototherapy for psoriasis. Combined therapy with suberythemogenic doses of fluorescent sunlamp ultraviolet radiation</article-title>
          <source>Arch Dermatol</source>
          <year>1979</year>
          <volume>115</volume>
          <issue>7</issue>
          <fpage>840</fpage>
          <lpage>846</lpage>
          <pub-id pub-id-type="doi">10.1001/archderm.115.7.840</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Frost P, Horwitz SN, Caputo RV, Berger SM (1979) Tar gel-phototherapy for psoriasis. Combined therapy with suberythemogenic doses of fluorescent sunlamp ultraviolet radiation. Arch Dermatol 115(7):840&#x2013;846 <pub-id pub-id-type="pmid">453892</pub-id></citation>
      </ref>
      <ref id="CR41">
        <label>41.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Weinstein</surname>
              <given-names>GD</given-names>
            </name>
            <name>
              <surname>Koo</surname>
              <given-names>JY</given-names>
            </name>
            <name>
              <surname>Krueger</surname>
              <given-names>GG</given-names>
            </name>
            <name>
              <surname>Lebwohl</surname>
              <given-names>MG</given-names>
            </name>
            <name>
              <surname>Lowe</surname>
              <given-names>NJ</given-names>
            </name>
            <name>
              <surname>Menter</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Lew-Kaya</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Sefton</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Gibson</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Walker</surname>
              <given-names>PS</given-names>
            </name>
          </person-group>
          <article-title>Tazarotene cream in the treatment of psoriasis: two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks</article-title>
          <source>J Am Acad Dermatol</source>
          <year>2003</year>
          <volume>48</volume>
          <issue>5</issue>
          <fpage>760</fpage>
          <lpage>767</lpage>
          <pub-id pub-id-type="doi">10.1067/mjd.2003.103</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Weinstein GD, Koo JY, Krueger GG, Lebwohl MG, Lowe NJ, Menter MA, Lew-Kaya DA, Sefton J, Gibson JR, Walker PS (2003) Tazarotene cream in the treatment of psoriasis: two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks. J Am Acad Dermatol 48(5):760&#x2013;767 <pub-id pub-id-type="pmid">12734506</pub-id></citation>
      </ref>
      <ref id="CR42">
        <label>42.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gollnick</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Menter</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Combination therapy with tazarotene plus a topical corticosteroid for the treatment of plaque psoriasis</article-title>
          <source>Br J Dermatol</source>
          <year>1999</year>
          <volume>140</volume>
          <issue>Suppl 54</issue>
          <fpage>18</fpage>
          <lpage>23</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1365-2133.1999.140S54018.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Gollnick H, Menter A (1999) Combination therapy with tazarotene plus a topical corticosteroid for the treatment of plaque psoriasis. Br J Dermatol 140(Suppl 54):18&#x2013;23 <pub-id pub-id-type="pmid">10731130</pub-id></citation>
      </ref>
      <ref id="CR43">
        <label>43.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Green</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Sadoff</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>A clinical evaluation of tazarotene 0.1% gel, with and without a high- or mid-high-potency corticosteroid, in patients with stable plaque psoriasis</article-title>
          <source>J Cutan Med Surg</source>
          <year>2002</year>
          <volume>6</volume>
          <issue>2</issue>
          <fpage>95</fpage>
          <lpage>102</lpage>
        </citation>
        <citation citation-type="display-unstructured">Green L, Sadoff W (2002) A clinical evaluation of tazarotene 0.1% gel, with and without a high- or mid-high-potency corticosteroid, in patients with stable plaque psoriasis. J Cutan Med Surg 6(2):95&#x2013;102 <pub-id pub-id-type="pmid">11992180</pub-id></citation>
      </ref>
      <ref id="CR44">
        <label>44.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Koo</surname>
              <given-names>JY</given-names>
            </name>
            <name>
              <surname>Martin</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Investigator-masked comparison of tazarotene gel q.d. plus mometasone furoate cream q.d. vs. mometasone furoate cream b.i.d. in the treatment of plaque psoriasis</article-title>
          <source>Int J Dermatol</source>
          <year>2001</year>
          <volume>40</volume>
          <issue>3</issue>
          <fpage>210</fpage>
          <lpage>212</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1365-4362.2001.01167.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Koo JY, Martin D (2001) Investigator-masked comparison of tazarotene gel q.d. plus mometasone furoate cream q.d. vs. mometasone furoate cream b.i.d. in the treatment of plaque psoriasis. Int J Dermatol 40(3):210&#x2013;212 <pub-id pub-id-type="pmid">11422529</pub-id></citation>
      </ref>
      <ref id="CR45">
        <label>45.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lebwohl</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Strategies to optimize efficacy, duration of remission, and safety in the treatment of plaque psoriasis by using tazarotene in combination with a corticosteroid</article-title>
          <source>J Am Acad Dermatol</source>
          <year>2000</year>
          <volume>43</volume>
          <issue>2 Pt 3</issue>
          <fpage>S43</fpage>
          <lpage>S46</lpage>
          <pub-id pub-id-type="doi">10.1067/mjd.2000.108319</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Lebwohl M (2000) Strategies to optimize efficacy, duration of remission, and safety in the treatment of plaque psoriasis by using tazarotene in combination with a corticosteroid. J Am Acad Dermatol 43(2 Pt 3):S43&#x2013;S46 <pub-id pub-id-type="pmid">10898829</pub-id></citation>
      </ref>
      <ref id="CR46">
        <label>46.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Poulin</surname>
              <given-names>YP</given-names>
            </name>
          </person-group>
          <article-title>Tazarotene 0.1% gel in combination with mometasone furoate cream in plaque psoriasis: a photographic tracking study</article-title>
          <source>Cutis</source>
          <year>1999</year>
          <volume>63</volume>
          <issue>1</issue>
          <fpage>41</fpage>
          <lpage>48</lpage>
        </citation>
        <citation citation-type="display-unstructured">Poulin YP (1999) Tazarotene 0.1% gel in combination with mometasone furoate cream in plaque psoriasis: a photographic tracking study. Cutis 63(1):41&#x2013;48 <pub-id pub-id-type="pmid">9951595</pub-id></citation>
      </ref>
      <ref id="CR47">
        <label>47.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kerkhof</surname>
              <given-names>PC</given-names>
            </name>
            <name>
              <surname>Green</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Hamberg</surname>
              <given-names>KJ</given-names>
            </name>
            <name>
              <surname>Hutchinson</surname>
              <given-names>PE</given-names>
            </name>
            <name>
              <surname>Jensen</surname>
              <given-names>JK</given-names>
            </name>
            <name>
              <surname>Kidson</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Kragballe</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Larsen</surname>
              <given-names>FG</given-names>
            </name>
            <name>
              <surname>Munro</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Tillman</surname>
              <given-names>DM</given-names>
            </name>
          </person-group>
          <article-title>Safety and efficacy of combined high-dose treatment with calcipotriol ointment and solution in patients with psoriasis</article-title>
          <source>Dermatology</source>
          <year>2002</year>
          <volume>204</volume>
          <issue>3</issue>
          <fpage>214</fpage>
          <lpage>221</lpage>
          <pub-id pub-id-type="doi">10.1159/000057884</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Van de Kerkhof PC, Green C, Hamberg KJ, Hutchinson PE, Jensen JK, Kidson P, Kragballe K, Larsen FG, Munro CS, Tillman DM (2002) Safety and efficacy of combined high-dose treatment with calcipotriol ointment and solution in patients with psoriasis. Dermatology 204(3):214&#x2013;221 <pub-id pub-id-type="pmid">12037450</pub-id></citation>
      </ref>
      <ref id="CR48">
        <label>48.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Guenther</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Kerkhof</surname>
              <given-names>PC</given-names>
            </name>
            <name>
              <surname>Snellman</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Kragballe</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Chu</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Tegner</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Garcia-Diez</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Springborg</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial</article-title>
          <source>Br J Dermatol</source>
          <year>2002</year>
          <volume>147</volume>
          <issue>2</issue>
          <fpage>316</fpage>
          <lpage>323</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1365-2133.2002.04967.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Guenther L, Van de Kerkhof PC, Snellman E, Kragballe K, Chu AC, Tegner E, Garcia-Diez A, Springborg J (2002) Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial. Br J Dermatol 147(2):316&#x2013;323 <pub-id pub-id-type="pmid">12174105</pub-id></citation>
      </ref>
      <ref id="CR49">
        <label>49.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kragballe</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Noerrelund</surname>
              <given-names>KL</given-names>
            </name>
            <name>
              <surname>Lui</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Ortonne</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Wozel</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Uurasmaa</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Fleming</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Estebaranz</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Hanssen</surname>
              <given-names>LI</given-names>
            </name>
            <name>
              <surname>Persson</surname>
              <given-names>LM</given-names>
            </name>
          </person-group>
          <article-title>Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris</article-title>
          <source>Br J Dermatol</source>
          <year>2004</year>
          <volume>150</volume>
          <issue>6</issue>
          <fpage>1167</fpage>
          <lpage>1173</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2133.2004.05986.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Kragballe K, Noerrelund KL, Lui H, Ortonne JP, Wozel G, Uurasmaa T, Fleming C, Estebaranz JL, Hanssen LI, Persson LM (2004) Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris. Br J Dermatol 150(6):1167&#x2013;1173 <pub-id pub-id-type="pmid">15214905</pub-id></citation>
      </ref>
      <ref id="CR50">
        <label>50.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ortonne</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Kaufmann</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Lecha</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Goodfield</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Efficacy of treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol for the treatment of psoriasis vulgaris: a randomised, double-blind trial</article-title>
          <source>Dermatology</source>
          <year>2004</year>
          <volume>209</volume>
          <issue>4</issue>
          <fpage>308</fpage>
          <lpage>313</lpage>
          <pub-id pub-id-type="doi">10.1159/000080854</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Ortonne JP, Kaufmann R, Lecha M, Goodfield M (2004) Efficacy of treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol for the treatment of psoriasis vulgaris: a randomised, double-blind trial. Dermatology 209(4):308&#x2013;313 <pub-id pub-id-type="pmid">15539894</pub-id></citation>
      </ref>
      <ref id="CR51">
        <label>51.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Guenther</surname>
              <given-names>LC</given-names>
            </name>
            <name>
              <surname>Poulin</surname>
              <given-names>YP</given-names>
            </name>
            <name>
              <surname>Pariser</surname>
              <given-names>DM</given-names>
            </name>
          </person-group>
          <article-title>A comparison of tazarotene 0.1% gel once daily plus mometasone furoate 0.1% cream once daily versus calcipotriene 0.005% ointment twice daily in the treatment of plaque psoriasis</article-title>
          <source>Clin Ther</source>
          <year>2000</year>
          <volume>22</volume>
          <issue>10</issue>
          <fpage>1225</fpage>
          <lpage>1238</lpage>
          <pub-id pub-id-type="doi">10.1016/S0149-2918(00)83065-9</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Guenther LC, Poulin YP, Pariser DM (2000) A comparison of tazarotene 0.1% gel once daily plus mometasone furoate 0.1% cream once daily versus calcipotriene 0.005% ointment twice daily in the treatment of plaque psoriasis. Clin Ther 22(10):1225&#x2013;1238 <pub-id pub-id-type="pmid">11110233</pub-id></citation>
      </ref>
      <ref id="CR52">
        <label>52.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lebwohl</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Yoles</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lombardi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Lou</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>Calcipotriene ointment and halobetasol ointment in the long-term treatment of psoriasis: effects on the duration of improvement</article-title>
          <source>J Am Acad Dermatol</source>
          <year>1998</year>
          <volume>39</volume>
          <issue>3</issue>
          <fpage>447</fpage>
          <lpage>450</lpage>
          <pub-id pub-id-type="doi">10.1016/S0190-9622(98)70323-8</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Lebwohl M, Yoles A, Lombardi K, Lou W (1998) Calcipotriene ointment and halobetasol ointment in the long-term treatment of psoriasis: effects on the duration of improvement. J Am Acad Dermatol 39(3):447&#x2013;450 <pub-id pub-id-type="pmid">9738781</pub-id></citation>
      </ref>
      <ref id="CR53">
        <label>53.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Diette</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Momtaz</surname>
              <given-names>TK</given-names>
            </name>
            <name>
              <surname>Stern</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Arndt</surname>
              <given-names>KA</given-names>
            </name>
            <name>
              <surname>Parrish</surname>
              <given-names>JA</given-names>
            </name>
          </person-group>
          <article-title>Psoralens and UV-A and UV-B twice weekly for the treatment of psoriasis</article-title>
          <source>Arch Dermatol</source>
          <year>1984</year>
          <volume>120</volume>
          <issue>9</issue>
          <fpage>1169</fpage>
          <lpage>1173</lpage>
          <pub-id pub-id-type="doi">10.1001/archderm.120.9.1169</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Diette KM, Momtaz TK, Stern RS, Arndt KA, Parrish JA (1984) Psoralens and UV-A and UV-B twice weekly for the treatment of psoriasis. Arch Dermatol 120(9):1169&#x2013;1173 <pub-id pub-id-type="pmid">6476854</pub-id></citation>
      </ref>
      <ref id="CR54">
        <label>54.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ramsay</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Schwartz</surname>
              <given-names>BE</given-names>
            </name>
            <name>
              <surname>Lowson</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Papp</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Bolduc</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gilbert</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Calcipotriol cream combined with twice weekly broad-band UVB phototherapy: a safe, effective and UVB-sparing antipsoriatric combination treatment. The Canadian Calcipotriol and UVB Study Group</article-title>
          <source>Dermatology</source>
          <year>2000</year>
          <volume>200</volume>
          <issue>1</issue>
          <fpage>17</fpage>
          <lpage>24</lpage>
          <pub-id pub-id-type="doi">10.1159/000018309</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Ramsay CA, Schwartz BE, Lowson D, Papp K, Bolduc A, Gilbert M (2000) Calcipotriol cream combined with twice weekly broad-band UVB phototherapy: a safe, effective and UVB-sparing antipsoriatric combination treatment. The Canadian Calcipotriol and UVB Study Group. Dermatology 200(1):17&#x2013;24 <pub-id pub-id-type="pmid">10681608</pub-id></citation>
      </ref>
      <ref id="CR55">
        <label>55.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ring</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kowalzick</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Christophers</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Schill</surname>
              <given-names>WB</given-names>
            </name>
            <name>
              <surname>Schopf</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Stander</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Wolff</surname>
              <given-names>HH</given-names>
            </name>
            <name>
              <surname>Altmeyer</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Calcitriol 3 microg g-1 ointment in combination with ultraviolet B phototherapy for the treatment of plaque psoriasis: results of a comparative study</article-title>
          <source>Br J Dermatol</source>
          <year>2001</year>
          <volume>144</volume>
          <issue>3</issue>
          <fpage>495</fpage>
          <lpage>499</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1365-2133.2001.04074.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Ring J, Kowalzick L, Christophers E, Schill WB, Schopf E, Stander M, Wolff HH, Altmeyer P (2001) Calcitriol 3 microg g-1 ointment in combination with ultraviolet B phototherapy for the treatment of plaque psoriasis: results of a comparative study. Br J Dermatol 144(3):495&#x2013;499 <pub-id pub-id-type="pmid">11260005</pub-id></citation>
      </ref>
      <ref id="CR56">
        <label>56.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Petrozzi</surname>
              <given-names>JW</given-names>
            </name>
          </person-group>
          <article-title>Topical steroids and UV radiation in psoriasis</article-title>
          <source>Arch Dermatol</source>
          <year>1983</year>
          <volume>119</volume>
          <issue>3</issue>
          <fpage>207</fpage>
          <lpage>210</lpage>
          <pub-id pub-id-type="doi">10.1001/archderm.119.3.207</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Petrozzi JW (1983) Topical steroids and UV radiation in psoriasis. Arch Dermatol 119(3):207&#x2013;210 <pub-id pub-id-type="pmid">6824358</pub-id></citation>
      </ref>
      <ref id="CR57">
        <label>57.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Coven</surname>
              <given-names>TR</given-names>
            </name>
            <name>
              <surname>Burack</surname>
              <given-names>LH</given-names>
            </name>
            <name>
              <surname>Gilleaudeau</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Keogh</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ozawa</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Krueger</surname>
              <given-names>JG</given-names>
            </name>
          </person-group>
          <article-title>Narrowband UV-B produces superior clinical and histopathological resolution of moderate-to-severe psoriasis in patients compared with broadband UVB</article-title>
          <source>Arch Dermatol</source>
          <year>1997</year>
          <volume>133</volume>
          <fpage>514</fpage>
          <lpage>522</lpage>
          <pub-id pub-id-type="doi">10.1001/archderm.133.12.1514</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Coven TR, Burack LH, Gilleaudeau R, Keogh M, Ozawa M, Krueger JG (1997) Narrowband UV-B produces superior clinical and histopathological resolution of moderate-to-severe psoriasis in patients compared with broadband UVB. Arch Dermatol 133:514&#x2013;522 </citation>
      </ref>
      <ref id="CR58">
        <label>58.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Snellman</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Klimenko</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Rantanen</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Randomized half-side comparison of narrowband UVB and trimethylpsoralen bath</article-title>
          <source>Acta Derm Venereol</source>
          <year>2004</year>
          <volume>84</volume>
          <issue>2</issue>
          <fpage>132</fpage>
          <lpage>137</lpage>
          <pub-id pub-id-type="doi">10.1080/00015550310022916</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Snellman E, Klimenko T, Rantanen T (2004) Randomized half-side comparison of narrowband UVB and trimethylpsoralen bath. Acta Derm Venereol 84(2):132&#x2013;137 <pub-id pub-id-type="pmid">15206693</pub-id></citation>
      </ref>
      <ref id="CR59">
        <label>59.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gordon</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Diffey</surname>
              <given-names>BL</given-names>
            </name>
            <name>
              <surname>Matthews</surname>
              <given-names>JNS</given-names>
            </name>
            <name>
              <surname>Farr</surname>
              <given-names>PM</given-names>
            </name>
          </person-group>
          <article-title>A randomised comparison of narrow-band TL-01 phototherapy and PUVA photochemotherapy for psoriasis</article-title>
          <source>J Am Acad Dermatol</source>
          <year>1999</year>
          <volume>41</volume>
          <fpage>728</fpage>
          <lpage>732</lpage>
          <pub-id pub-id-type="doi">10.1016/S0190-9622(99)70008-3</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Gordon PM, Diffey BL, Matthews JNS, Farr PM (1999) A randomised comparison of narrow-band TL-01 phototherapy and PUVA photochemotherapy for psoriasis. J Am Acad Dermatol 41:728&#x2013;732 <pub-id pub-id-type="pmid">10534635</pub-id></citation>
      </ref>
      <ref id="CR60">
        <label>60.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Leenutaphong</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Nimkulrat</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Sudtim</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Comparison of phototherapy two times and four times a week with low doses of narrow-band ultraviolet B in Asian patients with psoriasis</article-title>
          <source>Photodermatol Photoimmunol Photomed</source>
          <year>2000</year>
          <volume>16</volume>
          <issue>5</issue>
          <fpage>202</fpage>
          <lpage>206</lpage>
          <pub-id pub-id-type="doi">10.1034/j.1600-0781.2000.160502.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Leenutaphong V, Nimkulrat P, Sudtim S (2000) Comparison of phototherapy two times and four times a week with low doses of narrow-band ultraviolet B in Asian patients with psoriasis. Photodermatol Photoimmunol Photomed 16(5):202&#x2013;206 <pub-id pub-id-type="pmid">11068858</pub-id></citation>
      </ref>
      <ref id="CR61">
        <label>61.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Grundmann-Kollmann</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ludwig</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Zollner</surname>
              <given-names>TM</given-names>
            </name>
            <name>
              <surname>Ochsendorf</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Thaci</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Boehncke</surname>
              <given-names>WH</given-names>
            </name>
            <name>
              <surname>Krutmann</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kaufmann</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Podda</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Narrowband UVB and cream psoralen-UVA combination therapy for plaque-type psoriasis</article-title>
          <source>J Am Acad Dermatol</source>
          <year>2004</year>
          <volume>50</volume>
          <issue>5</issue>
          <fpage>734</fpage>
          <lpage>739</lpage>
          <pub-id pub-id-type="doi">10.1016/S0190-9622(03)00792-8</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Grundmann-Kollmann M, Ludwig R, Zollner TM, Ochsendorf F, Thaci D, Boehncke WH, Krutmann J, Kaufmann R, Podda M (2004) Narrowband UVB and cream psoralen-UVA combination therapy for plaque-type psoriasis. J Am Acad Dermatol 50(5):734&#x2013;739 <pub-id pub-id-type="pmid">15097957</pub-id></citation>
      </ref>
      <ref id="CR62">
        <label>62.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Katugampola</surname>
              <given-names>GA</given-names>
            </name>
            <name>
              <surname>Rees</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Lanigan</surname>
              <given-names>SW</given-names>
            </name>
          </person-group>
          <article-title>Laser treatment of psoriasis</article-title>
          <source>Br J Dermatol</source>
          <year>1995</year>
          <volume>133</volume>
          <issue>6</issue>
          <fpage>909</fpage>
          <lpage>913</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2133.1995.tb06924.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Katugampola GA, Rees AM, Lanigan SW (1995) Laser treatment of psoriasis. Br J Dermatol 133(6):909&#x2013;913 <pub-id pub-id-type="pmid">8547043</pub-id></citation>
      </ref>
      <ref id="CR63">
        <label>63.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Housman</surname>
              <given-names>TS</given-names>
            </name>
            <name>
              <surname>Pearce</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Feldman</surname>
              <given-names>SR</given-names>
            </name>
          </person-group>
          <article-title>A maintenance protocol for psoriasis plaques cleared by the 308 nm excimer laser</article-title>
          <source>J Dermatol Treat</source>
          <year>2004</year>
          <volume>15</volume>
          <issue>2</issue>
          <fpage>94</fpage>
          <lpage>97</lpage>
          <pub-id pub-id-type="doi">10.1080/09546630310021947</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Housman TS, Pearce DJ, Feldman SR (2004) A maintenance protocol for psoriasis plaques cleared by the 308 nm excimer laser. J Dermatol Treat 15(2):94&#x2013;97 </citation>
      </ref>
      <ref id="CR64">
        <label>64.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Trehan</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Taylor</surname>
              <given-names>CR</given-names>
            </name>
          </person-group>
          <article-title>Medium-dose 308-nm excimer laser for the treatment of psoriasis</article-title>
          <source>J Am Acad Dermatol</source>
          <year>2002</year>
          <volume>47</volume>
          <issue>5</issue>
          <fpage>701</fpage>
          <lpage>708</lpage>
          <pub-id pub-id-type="doi">10.1067/mjd.2002.125075</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Trehan M, Taylor CR (2002) Medium-dose 308-nm excimer laser for the treatment of psoriasis. J Am Acad Dermatol 47(5):701&#x2013;708 <pub-id pub-id-type="pmid">12399761</pub-id></citation>
      </ref>
      <ref id="CR65">
        <label>65.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Feldman</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Mellen</surname>
              <given-names>BG</given-names>
            </name>
            <name>
              <surname>Housman</surname>
              <given-names>TS</given-names>
            </name>
            <name>
              <surname>Fitzpatrick</surname>
              <given-names>RE</given-names>
            </name>
            <name>
              <surname>Geronemus</surname>
              <given-names>RG</given-names>
            </name>
            <name>
              <surname>Friedman</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Vasily</surname>
              <given-names>DB</given-names>
            </name>
            <name>
              <surname>Morison</surname>
              <given-names>WL</given-names>
            </name>
          </person-group>
          <article-title>Efficacy of the 308-nm excimer laser for treatment of psoriasis: results of a multicenter study</article-title>
          <source>J Am Acad Dermatol</source>
          <year>2002</year>
          <volume>46</volume>
          <issue>6</issue>
          <fpage>900</fpage>
          <lpage>906</lpage>
          <pub-id pub-id-type="doi">10.1067/mjd.2002.120454</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Feldman SR, Mellen BG, Housman TS, Fitzpatrick RE, Geronemus RG, Friedman PM, Vasily DB, Morison WL (2002) Efficacy of the 308-nm excimer laser for treatment of psoriasis: results of a multicenter study. J Am Acad Dermatol 46(6):900&#x2013;906 <pub-id pub-id-type="pmid">12063488</pub-id></citation>
      </ref>
      <ref id="CR66">
        <label>66.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Parrish</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Fitzpatrick</surname>
              <given-names>TB</given-names>
            </name>
            <name>
              <surname>Tannenbaum</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Pathak</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
          <article-title>Photochemotherapy of psoriasis with oral methoxsalen and longwave ultraviolet light</article-title>
          <source>N Engl J Med</source>
          <year>1974</year>
          <volume>291</volume>
          <fpage>1207</fpage>
          <lpage>1211</lpage>
        </citation>
        <citation citation-type="display-unstructured">Parrish JA, Fitzpatrick TB, Tannenbaum L, Pathak MA (1974) Photochemotherapy of psoriasis with oral methoxsalen and longwave ultraviolet light. N Engl J Med 291:1207&#x2013;1211 <pub-id pub-id-type="pmid">4422691</pub-id></citation>
      </ref>
      <ref id="CR67">
        <label>67.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kirby</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Buckley</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Rogers</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Large increments in psoralen-ultraviolet A (PUVA) therapy are unsuitable for fair-skinned individuals with psoriasis</article-title>
          <source>Br J Dermatol</source>
          <year>1999</year>
          <volume>140</volume>
          <issue>4</issue>
          <fpage>661</fpage>
          <lpage>666</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1365-2133.1999.02766.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Kirby B, Buckley DA, Rogers S (1999) Large increments in psoralen-ultraviolet A (PUVA) therapy are unsuitable for fair-skinned individuals with psoriasis. Br J Dermatol 140(4):661&#x2013;666 <pub-id pub-id-type="pmid">10233317</pub-id></citation>
      </ref>
      <ref id="CR68">
        <label>68.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Buckley</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Healy</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Rogers</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>A comparison of twice-weekly MPD-PUVA and three times-weekly skin typing-PUVA regimens for the treatment of psoriasis</article-title>
          <source>Br J Dermatol</source>
          <year>1995</year>
          <volume>133</volume>
          <issue>3</issue>
          <fpage>417</fpage>
          <lpage>422</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2133.1995.tb02670.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Buckley DA, Healy E, Rogers S (1995) A comparison of twice-weekly MPD-PUVA and three times-weekly skin typing-PUVA regimens for the treatment of psoriasis. Br J Dermatol 133(3):417&#x2013;422 <pub-id pub-id-type="pmid">8546997</pub-id></citation>
      </ref>
      <ref id="CR69">
        <label>69.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Berg</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ros</surname>
              <given-names>AM</given-names>
            </name>
          </person-group>
          <article-title>Treatment of psoriasis with psoralens and ultraviolet A. A double-blind comparison of 8-methoxypsoralen and 5-methoxypsoralen</article-title>
          <source>Photodermatol Photoimmunol Photomed</source>
          <year>1994</year>
          <volume>10</volume>
          <fpage>217</fpage>
          <lpage>220</lpage>
        </citation>
        <citation citation-type="display-unstructured">Berg M, Ros AM (1994) Treatment of psoriasis with psoralens and ultraviolet A. A double-blind comparison of 8-methoxypsoralen and 5-methoxypsoralen. Photodermatol Photoimmunol Photomed 10:217&#x2013;220 <pub-id pub-id-type="pmid">7880762</pub-id></citation>
      </ref>
      <ref id="CR70">
        <label>70.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cooper</surname>
              <given-names>EJ</given-names>
            </name>
            <name>
              <surname>Herd</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Priestley</surname>
              <given-names>GC</given-names>
            </name>
            <name>
              <surname>Hunter</surname>
              <given-names>JA</given-names>
            </name>
          </person-group>
          <article-title>A comparison of bathwater and oral delivery of 8-methoxypsoralen in PUVA therapy for plaque psoriasis</article-title>
          <source>Clin Exp Dermatol</source>
          <year>2000</year>
          <volume>25</volume>
          <issue>2</issue>
          <fpage>111</fpage>
          <lpage>114</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1365-2230.2000.00589.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Cooper EJ, Herd RM, Priestley GC, Hunter JA (2000) A comparison of bathwater and oral delivery of 8-methoxypsoralen in PUVA therapy for plaque psoriasis. Clin Exp Dermatol 25(2):111&#x2013;114 <pub-id pub-id-type="pmid">10733632</pub-id></citation>
      </ref>
      <ref id="CR71">
        <label>71.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Collins</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Rogers</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Bath-water compared with oral delivery of 8-methoxypsoralen PUVA therapy for chronic plaque psoriasis</article-title>
          <source>Br J Dermatol</source>
          <year>1992</year>
          <volume>127</volume>
          <issue>4</issue>
          <fpage>392</fpage>
          <lpage>395</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2133.1992.tb00460.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Collins P, Rogers S (1992) Bath-water compared with oral delivery of 8-methoxypsoralen PUVA therapy for chronic plaque psoriasis. Br J Dermatol 127(4):392&#x2013;395 <pub-id pub-id-type="pmid">1419760</pub-id></citation>
      </ref>
      <ref id="CR72">
        <label>72.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Calzavara-Pinton</surname>
              <given-names>PG</given-names>
            </name>
            <name>
              <surname>Ortel</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Honigsmann</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Zane</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Panfilis</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Safety and effectiveness of an aggressive and individualized bath-PUVA regimen in the treatment of psoriasis</article-title>
          <source>Dermatology</source>
          <year>1994</year>
          <volume>189</volume>
          <issue>3</issue>
          <fpage>256</fpage>
          <lpage>259</lpage>
        </citation>
        <citation citation-type="display-unstructured">Calzavara-Pinton PG, Ortel B, Honigsmann H, Zane C, De Panfilis G (1994) Safety and effectiveness of an aggressive and individualized bath-PUVA regimen in the treatment of psoriasis. Dermatology 189(3):256&#x2013;259 <pub-id pub-id-type="pmid">7949478</pub-id></citation>
      </ref>
      <ref id="CR73">
        <label>73.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Barth</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Dietz</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Heilmann</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kadner</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kraensel</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Meffert</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Metz</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Pinzer</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Schiller</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Fotochemotherapie mit 8-methoxypsoralen und UVA bei Psoriasis vulgaris</article-title>
          <source>Dermatol Monatsschr</source>
          <year>1978</year>
          <volume>164</volume>
          <issue>6</issue>
          <fpage>401</fpage>
          <lpage>407</lpage>
        </citation>
        <citation citation-type="display-unstructured">Barth J, Dietz O, Heilmann S, Kadner H, Kraensel H, Meffert H, Metz D, Pinzer B, Schiller F (1978) Fotochemotherapie mit 8-methoxypsoralen und UVA bei Psoriasis vulgaris. Dermatol Monatsschr 164(6):401&#x2013;407 <pub-id pub-id-type="pmid">357211</pub-id></citation>
      </ref>
      <ref id="CR74">
        <label>74.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Khurshid</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Haroon</surname>
              <given-names>TS</given-names>
            </name>
            <name>
              <surname>Hussain</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Pal</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Jahangir</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Zaman</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Psoralen-ultraviolet A therapy vs. psoralen-ultraviolet B therapy in the treatment of plaque-type psoriasis: our experience with fitzpatrick skin type IV</article-title>
          <source>Int J Dermatol</source>
          <year>2000</year>
          <volume>39</volume>
          <issue>11</issue>
          <fpage>865</fpage>
          <lpage>867</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1365-4362.2000.00913.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Khurshid K, Haroon TS, Hussain I, Pal SS, Jahangir M, Zaman T (2000) Psoralen-ultraviolet A therapy vs. psoralen-ultraviolet B therapy in the treatment of plaque-type psoriasis: our experience with fitzpatrick skin type IV. Int J Dermatol 39(11):865&#x2013;867 <pub-id pub-id-type="pmid">11123453</pub-id></citation>
      </ref>
      <ref id="CR75">
        <label>75.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Arnold</surname>
              <given-names>WP</given-names>
            </name>
            <name>
              <surname>Andel</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Hoop</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Jong-Tieben</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Visser-van Andel</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>A comparison of the effect of narrow-band ultraviolet B in the treatment of psoriasis after salt-water baths and after 8-methoxypsoralen baths</article-title>
          <source>Br J Dermatol</source>
          <year>2001</year>
          <volume>145</volume>
          <issue>2</issue>
          <fpage>352</fpage>
          <lpage>354</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1365-2133.2001.04355.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Arnold WP, van Andel P, de Hoop D, de Jong-Tieben L, Visser-van Andel M (2001) A comparison of the effect of narrow-band ultraviolet B in the treatment of psoriasis after salt-water baths and after 8-methoxypsoralen baths. Br J Dermatol 145(2):352&#x2013;354 <pub-id pub-id-type="pmid">11531811</pub-id></citation>
      </ref>
      <ref id="CR76">
        <label>76.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Park</surname>
              <given-names>YK</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Koh</surname>
              <given-names>YJ</given-names>
            </name>
          </person-group>
          <article-title>Combination of photochemotherapy (PUVA) and ultraviolet B (UVB) in the treatment of psoriasis vulgaris</article-title>
          <source>J Dermatol</source>
          <year>1988</year>
          <volume>15</volume>
          <issue>1</issue>
          <fpage>68</fpage>
          <lpage>71</lpage>
        </citation>
        <citation citation-type="display-unstructured">Park YK, Kim HJ, Koh YJ (1988) Combination of photochemotherapy (PUVA) and ultraviolet B (UVB) in the treatment of psoriasis vulgaris. J Dermatol 15(1): 68&#x2013;71 <pub-id pub-id-type="pmid">3292621</pub-id></citation>
      </ref>
      <ref id="CR77">
        <label>77.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kabat-Zinn</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Wheeler</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Light</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Skillings</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Scharf</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Cropley</surname>
              <given-names>TG</given-names>
            </name>
            <name>
              <surname>Hosmer</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Bernhard</surname>
              <given-names>JD</given-names>
            </name>
          </person-group>
          <article-title>Influence of a mindfulness meditation-based stress reduction intervention on rates of skin clearing in patients with moderate to severe psoriasis undergoing phototherapy (UVB) and photochemotherapy (PUVA)</article-title>
          <source>Psychosom Med</source>
          <year>1998</year>
          <volume>60</volume>
          <issue>5</issue>
          <fpage>625</fpage>
          <lpage>632</lpage>
        </citation>
        <citation citation-type="display-unstructured">Kabat-Zinn J, Wheeler E, Light T, Skillings A, Scharf MJ, Cropley TG, Hosmer D, Bernhard JD (1998) Influence of a mindfulness meditation-based stress reduction intervention on rates of skin clearing in patients with moderate to severe psoriasis undergoing phototherapy (UVB) and photochemotherapy (PUVA). Psychosom Med 60(5):625&#x2013;632 <pub-id pub-id-type="pmid">9773769</pub-id></citation>
      </ref>
      <ref id="CR78">
        <label>78.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Frappaz</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Thivolet</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Calcipotriol in combination with PUVA: a randomized double blind placebo study in severe psoriasis</article-title>
          <source>Eur J Dermatol</source>
          <year>1993</year>
          <volume>3</volume>
          <fpage>351</fpage>
          <lpage>354</lpage>
        </citation>
        <citation citation-type="display-unstructured">Frappaz A, Thivolet J (1993) Calcipotriol in combination with PUVA: a randomized double blind placebo study in severe psoriasis. Eur J Dermatol 3:351&#x2013;354 </citation>
      </ref>
      <ref id="CR79">
        <label>79.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rogers</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Marks</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Shuster</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Briffa</surname>
              <given-names>DV</given-names>
            </name>
            <name>
              <surname>Warin</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Greaves</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Comparison of photochemotherapy and dithranol in the treatment of chronic plaque psoriasis</article-title>
          <source>Lancet</source>
          <year>1979</year>
          <volume>1</volume>
          <issue>8114</issue>
          <fpage>455</fpage>
          <lpage>458</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(79)90820-1</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Rogers S, Marks J, Shuster S, Briffa DV, Warin A, Greaves M (1979) Comparison of photochemotherapy and dithranol in the treatment of chronic plaque psoriasis. Lancet 1(8114):455&#x2013;458 <pub-id pub-id-type="pmid">85052</pub-id></citation>
      </ref>
      <ref id="CR80">
        <label>80.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vella Briffa</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Rogers</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Greaves</surname>
              <given-names>MW</given-names>
            </name>
            <name>
              <surname>Marks</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Shuster</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Warin</surname>
              <given-names>AP</given-names>
            </name>
          </person-group>
          <article-title>A randomized, controlled clinical trial comparing photochemotherapy with dithranol in the initial treatment of chronic plaque psoriasis</article-title>
          <source>Clin Exp Dermatol</source>
          <year>1978</year>
          <volume>3</volume>
          <issue>4</issue>
          <fpage>339</fpage>
          <lpage>347</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2230.1978.tb01512.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Vella Briffa D, Rogers S, Greaves MW, Marks J, Shuster S, Warin AP (1978) A randomized, controlled clinical trial comparing photochemotherapy with dithranol in the initial treatment of chronic plaque psoriasis. Clin Exp Dermatol 3(4):339&#x2013;347 <pub-id pub-id-type="pmid">367644</pub-id></citation>
      </ref>
      <ref id="CR81">
        <label>81.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Parker</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Coburn</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Lawrence</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Marks</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Shuster</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>A randomized double-blind comparison of PUVA-etretinate and PUVA-placebo in the treatment of chronic plaque psoriasis</article-title>
          <source>Br J Dermatol</source>
          <year>1984</year>
          <volume>110</volume>
          <issue>2</issue>
          <fpage>215</fpage>
          <lpage>220</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2133.1984.tb07470.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Parker S, Coburn P, Lawrence C, Marks J, Shuster S (1984) A randomized double-blind comparison of PUVA-etretinate and PUVA-placebo in the treatment of chronic plaque psoriasis. Br J Dermatol 110(2):215&#x2013;220 <pub-id pub-id-type="pmid">6365147</pub-id></citation>
      </ref>
      <ref id="CR82">
        <label>82.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dover</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>McEvoy</surname>
              <given-names>MT</given-names>
            </name>
            <name>
              <surname>Rosen</surname>
              <given-names>CF</given-names>
            </name>
            <name>
              <surname>Arndt</surname>
              <given-names>KA</given-names>
            </name>
            <name>
              <surname>Stern</surname>
              <given-names>RS</given-names>
            </name>
          </person-group>
          <article-title>Are topical corticosteroids useful in phototherapy for psoriasis?</article-title>
          <source>J Am Acad Dermatol</source>
          <year>1989</year>
          <volume>20</volume>
          <issue>5 Pt 1</issue>
          <fpage>748</fpage>
          <lpage>754</lpage>
        </citation>
        <citation citation-type="display-unstructured">Dover JS, McEvoy MT, Rosen CF, Arndt KA, Stern RS (1989) Are topical corticosteroids useful in phototherapy for psoriasis? J Am Acad Dermatol 20(5 Pt 1):748&#x2013;754 <pub-id pub-id-type="pmid">2654215</pub-id></citation>
      </ref>
      <ref id="CR83">
        <label>83.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hanke</surname>
              <given-names>CW</given-names>
            </name>
            <name>
              <surname>Steck</surname>
              <given-names>WD</given-names>
            </name>
            <name>
              <surname>Roenigk</surname>
              <given-names>HH</given-names>
            </name>
          </person-group>
          <article-title>Combination therapy for psoriasis. Psoralens plus long-wave ultraviolet radiation with betamethasone valerate</article-title>
          <source>Arch Dermatol</source>
          <year>1979</year>
          <volume>115</volume>
          <issue>9</issue>
          <fpage>1074</fpage>
          <lpage>1077</lpage>
          <pub-id pub-id-type="doi">10.1001/archderm.115.9.1074</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Hanke CW, Steck WD, Roenigk HH Jr (1979) Combination therapy for psoriasis. Psoralens plus long-wave ultraviolet radiation with betamethasone valerate. Arch Dermatol 115(9):1074&#x2013;1077 <pub-id pub-id-type="pmid">485184</pub-id></citation>
      </ref>
      <ref id="CR84">
        <label>84.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Koo</surname>
              <given-names>JY</given-names>
            </name>
            <name>
              <surname>Lowe</surname>
              <given-names>NJ</given-names>
            </name>
            <name>
              <surname>Lew-Kaya</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Vasilopoulos</surname>
              <given-names>AI</given-names>
            </name>
            <name>
              <surname>Lue</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Sefton</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Gibson</surname>
              <given-names>JR</given-names>
            </name>
          </person-group>
          <article-title>Tazarotene plus UVB phototherapy in the treatment of psoriasis</article-title>
          <source>J Am Acad Dermatol</source>
          <year>2000</year>
          <volume>43</volume>
          <issue>5 Pt 1</issue>
          <fpage>821</fpage>
          <lpage>828</lpage>
          <pub-id pub-id-type="doi">10.1067/mjd.2000.107940</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Koo JY, Lowe NJ, Lew-Kaya DA, Vasilopoulos AI, Lue JC, Sefton J, Gibson JR (2000) Tazarotene plus UVB phototherapy in the treatment of psoriasis. J Am Acad Dermatol 43(5 Pt 1):821&#x2013;828 <pub-id pub-id-type="pmid">11050587</pub-id></citation>
      </ref>
      <ref id="CR85">
        <label>85.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McBride</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Walker</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Reynolds</surname>
              <given-names>NJ</given-names>
            </name>
          </person-group>
          <article-title>Optimizing the frequency of outpatient short-contact dithranol treatment used in combination with broadband ultraviolet B for psoriasis: a randomized, within-patient controlled trial</article-title>
          <source>Br J Dermatol</source>
          <year>2003</year>
          <volume>149</volume>
          <issue>6</issue>
          <fpage>1259</fpage>
          <lpage>1265</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2133.2003.05653.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">McBride SR, Walker P, Reynolds NJ (2003) Optimizing the frequency of outpatient short-contact dithranol treatment used in combination with broadband ultraviolet B for psoriasis: a randomized, within-patient controlled trial. Br J Dermatol 149(6):1259&#x2013;1265 <pub-id pub-id-type="pmid">14674905</pub-id></citation>
      </ref>
      <ref id="CR86">
        <label>86.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Levell</surname>
              <given-names>NJ</given-names>
            </name>
            <name>
              <surname>Shuster</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Munro</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Friedmann</surname>
              <given-names>PS</given-names>
            </name>
          </person-group>
          <article-title>Remission of ordinary psoriasis following a short clearance course of cyclosporin</article-title>
          <source>Acta Derm Venereol</source>
          <year>1995</year>
          <volume>75</volume>
          <issue>1</issue>
          <fpage>65</fpage>
          <lpage>69</lpage>
        </citation>
        <citation citation-type="display-unstructured">Levell NJ, Shuster S, Munro CS, Friedmann PS (1995) Remission of ordinary psoriasis following a short clearance course of cyclosporin. Acta Derm Venereol 75(1):65&#x2013;69 <pub-id pub-id-type="pmid">7747540</pub-id></citation>
      </ref>
      <ref id="CR87">
        <label>87.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Petzelbauer</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Honigsmann</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Langer</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Anegg</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Strohal</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Tanew</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Wolff</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Cyclosporin A in combination with photochemotherapy (PUVA) in the treatment of psoriasis</article-title>
          <source>Br J Dermatol</source>
          <year>1990</year>
          <volume>123</volume>
          <issue>5</issue>
          <fpage>641</fpage>
          <lpage>647</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2133.1990.tb01481.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Petzelbauer P, Honigsmann H, Langer K, Anegg B, Strohal R, Tanew A, Wolff K (1990) Cyclosporin A in combination with photochemotherapy (PUVA) in the treatment of psoriasis. Br J Dermatol 123(5):641&#x2013;647 <pub-id pub-id-type="pmid">2248892</pub-id></citation>
      </ref>
      <ref id="CR88">
        <label>88.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Franchi</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Cainelli</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Frigerio</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Garutti</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Altomare</surname>
              <given-names>GF</given-names>
            </name>
          </person-group>
          <article-title>Association of cyclosporine and 311 nm UVB in the treatment of moderate to severe forms of psoriasis: a new strategic approach</article-title>
          <source>Int J Immunopathol Pharmacol</source>
          <year>2004</year>
          <volume>17</volume>
          <issue>3</issue>
          <fpage>401</fpage>
          <lpage>406</lpage>
        </citation>
        <citation citation-type="display-unstructured">Franchi C, Cainelli G, Frigerio E, Garutti C, Altomare GF (2004) Association of cyclosporine and 311 nm UVB in the treatment of moderate to severe forms of psoriasis: a new strategic approach. Int J Immunopathol Pharmacol 17(3):401&#x2013;406 <pub-id pub-id-type="pmid">15461875</pub-id></citation>
      </ref>
      <ref id="CR89">
        <label>89.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Paul</surname>
              <given-names>BS</given-names>
            </name>
            <name>
              <surname>Momtaz</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Stern</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Arndt</surname>
              <given-names>KA</given-names>
            </name>
            <name>
              <surname>Parrish</surname>
              <given-names>JA</given-names>
            </name>
          </person-group>
          <article-title>Combined methotrexate&#x2013;ultraviolet B therapy in the treatment of psoriasis</article-title>
          <source>J Am Acad Dermatol</source>
          <year>1982</year>
          <volume>7</volume>
          <issue>6</issue>
          <fpage>758</fpage>
          <lpage>762</lpage>
        </citation>
        <citation citation-type="display-unstructured">Paul BS, Momtaz K, Stern RS, Arndt KA, Parrish JA (1982) Combined methotrexate&#x2013;ultraviolet B therapy in the treatment of psoriasis. J Am Acad Dermatol 7(6):758&#x2013;762 <pub-id pub-id-type="pmid">7174914</pub-id></citation>
      </ref>
      <ref id="CR90">
        <label>90.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Morison</surname>
              <given-names>WL</given-names>
            </name>
            <name>
              <surname>Momtaz</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Parrish</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Fitzpatrick</surname>
              <given-names>TB</given-names>
            </name>
          </person-group>
          <article-title>Combined methotrexate-PUVA therapy in the treatment of psoriasis</article-title>
          <source>J Am Acad Dermatol</source>
          <year>1982</year>
          <volume>6</volume>
          <issue>1</issue>
          <fpage>46</fpage>
          <lpage>51</lpage>
        </citation>
        <citation citation-type="display-unstructured">Morison WL, Momtaz K, Parrish JA, Fitzpatrick TB (1982) Combined methotrexate-PUVA therapy in the treatment of psoriasis. J Am Acad Dermatol 6(1):46&#x2013;51 <pub-id pub-id-type="pmid">7085955</pub-id></citation>
      </ref>
      <ref id="CR91">
        <label>91.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Caca-Biljanovska</surname>
              <given-names>NG</given-names>
            </name>
            <name>
              <surname>V&#x2019;Lckova-Laskoska</surname>
              <given-names>MT</given-names>
            </name>
          </person-group>
          <article-title>Management of guttate and generalized psoriasis vulgaris: prospective randomized study</article-title>
          <source>Croat Med J</source>
          <year>2002</year>
          <volume>43</volume>
          <issue>6</issue>
          <fpage>707</fpage>
          <lpage>712</lpage>
        </citation>
        <citation citation-type="display-unstructured">Caca-Biljanovska NG, V&#x2019;Lckova-Laskoska MT (2002) Management of guttate and generalized psoriasis vulgaris: prospective randomized study. Croat Med J 43(6): 707&#x2013;712 <pub-id pub-id-type="pmid">12476481</pub-id></citation>
      </ref>
      <ref id="CR92">
        <label>92.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Saurat</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Geiger</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Amblard</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Beau</surname>
              <given-names>J-C</given-names>
            </name>
            <name>
              <surname>Boulanger</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Claudy</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Randomized double-blind multicenter study comparing acitretin-PUVA and placebo-PUVA in the treatment of severe psoriasis</article-title>
          <source>Dermatoligica</source>
          <year>1988</year>
          <volume>177</volume>
          <fpage>218</fpage>
          <lpage>224</lpage>
        </citation>
        <citation citation-type="display-unstructured">Saurat JH, Geiger JM, Amblard P, Beau J-C, Boulanger A, Claudy A et al (1988) Randomized double-blind multicenter study comparing acitretin-PUVA and placebo-PUVA in the treatment of severe psoriasis. Dermatoligica 177:218&#x2013;224 </citation>
      </ref>
      <ref id="CR93">
        <label>93.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lauharanta</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Geiger</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
          <article-title>A double-blind comparison of acitretin and etretinate in combination with bath PUVA in the treatment of extensive psoriasis</article-title>
          <source>Br J Dermatol</source>
          <year>1989</year>
          <volume>121</volume>
          <issue>1</issue>
          <fpage>107</fpage>
          <lpage>112</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2133.1989.tb01406.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Lauharanta J, Geiger JM (1989) A double-blind comparison of acitretin and etretinate in combination with bath PUVA in the treatment of extensive psoriasis. Br J Dermatol 121(1):107&#x2013;112 <pub-id pub-id-type="pmid">2527054</pub-id></citation>
      </ref>
      <ref id="CR94">
        <label>94.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Orfanos</surname>
              <given-names>CE</given-names>
            </name>
            <name>
              <surname>Steigleder</surname>
              <given-names>GK</given-names>
            </name>
            <name>
              <surname>Pullmann</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Bloch</surname>
              <given-names>PH</given-names>
            </name>
          </person-group>
          <article-title>Oral retinoid and UVB radiation: a new, alternative treatment for psoriasis on an out-patient basis</article-title>
          <source>Acta Derm Venereol</source>
          <year>1979</year>
          <volume>59</volume>
          <issue>3</issue>
          <fpage>241</fpage>
          <lpage>244</lpage>
        </citation>
        <citation citation-type="display-unstructured">Orfanos CE, Steigleder GK, Pullmann H, Bloch PH (1979) Oral retinoid and UVB radiation: a new, alternative treatment for psoriasis on an out-patient basis. Acta Derm Venereol 59(3):241&#x2013;244 <pub-id pub-id-type="pmid">87082</pub-id></citation>
      </ref>
      <ref id="CR95">
        <label>95.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Calzavara-Pinton</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Narrow band UVB (311 nm) phototherapy and PUVA photochemotherapy: a combination</article-title>
          <source>J Am Acad Dermatol</source>
          <year>1998</year>
          <volume>38</volume>
          <issue>5 Pt 1</issue>
          <fpage>687</fpage>
          <lpage>690</lpage>
        </citation>
        <citation citation-type="display-unstructured">Calzavara-Pinton P (1998) Narrow band UVB (311 nm) phototherapy and PUVA photochemotherapy: a combination. J Am Acad Dermatol 38(5 Pt 1):687&#x2013;690 <pub-id pub-id-type="pmid">9591811</pub-id></citation>
      </ref>
      <ref id="CR96">
        <label>96.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Markham</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Rogers</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Collins</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Narrowband UV-B (TL-01) phototherapy vs oral 8-methoxypsoralen psoralen-UV-A for the treatment of chronic plaque psoriasis</article-title>
          <source>Arch Dermatol</source>
          <year>2003</year>
          <volume>139</volume>
          <issue>3</issue>
          <fpage>325</fpage>
          <lpage>328</lpage>
          <pub-id pub-id-type="doi">10.1001/archderm.139.3.325</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Markham T, Rogers S, Collins P (2003) Narrowband UV-B (TL-01) phototherapy vs oral 8-methoxypsoralen psoralen-UV-A for the treatment of chronic plaque psoriasis. Arch Dermatol 139(3):325&#x2013;328 <pub-id pub-id-type="pmid">12622624</pub-id></citation>
      </ref>
      <ref id="CR97">
        <label>97.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Calzavara-Pinton</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Ortel</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Carlino</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Honigsmann</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Panfilis</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>A reappraisal of the use of 5-methoxypsoralen in the therapy of psoriasis</article-title>
          <source>Exp Dermatol</source>
          <year>1992</year>
          <volume>1</volume>
          <issue>1</issue>
          <fpage>46</fpage>
          <lpage>51</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1600-0625.1992.tb00071.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Calzavara-Pinton P, Ortel B, Carlino A, Honigsmann H, De Panfilis G (1992) A reappraisal of the use of 5-methoxypsoralen in the therapy of psoriasis. Exp Dermatol 1(1):46&#x2013;51 <pub-id pub-id-type="pmid">1344660</pub-id></citation>
      </ref>
      <ref id="CR98">
        <label>98.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Henseler</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Wolff</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>H&#xF6;nigsmann</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Christophers</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Oral 8-methoxypsoralen photochemotherapy of psoriasis. The European PUVA Study: a cooperative study among 18 European centres</article-title>
          <source>Lancet</source>
          <year>1981</year>
          <volume>11</volume>
          <fpage>853</fpage>
          <lpage>857</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(81)92137-1</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Henseler T, Wolff K, H&#xF6;nigsmann H, Christophers E (1981) Oral 8-methoxypsoralen photochemotherapy of psoriasis. The European PUVA Study: a cooperative study among 18 European centres. Lancet 11:853&#x2013;857 <pub-id pub-id-type="pmid">6112291</pub-id></citation>
      </ref>
      <ref id="CR99">
        <label>99.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Torras</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Aliaga</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lopez-Estebaranz</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Hernandez</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Gardeazabal</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Quintanilla</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Mascaro</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
          <article-title>A combination therapy of calcipotriol cream and PUVA reduces the UVA dose and improves the response of psoriasis vulgaris</article-title>
          <source>J Dermatol Treat</source>
          <year>2004</year>
          <volume>15</volume>
          <issue>2</issue>
          <fpage>98</fpage>
          <lpage>103</lpage>
          <pub-id pub-id-type="doi">10.1080/09546630410023322</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Torras H, Aliaga A, Lopez-Estebaranz JL, Hernandez I, Gardeazabal J, Quintanilla E, Mascaro JM (2004) A combination therapy of calcipotriol cream and PUVA reduces the UVA dose and improves the response of psoriasis vulgaris. J Dermatol Treat 15(2):98&#x2013;103 </citation>
      </ref>
      <ref id="CR100">
        <label>100.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hacker</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Rasmussen</surname>
              <given-names>JE</given-names>
            </name>
          </person-group>
          <article-title>The effect of flash lamp-pulsed dye laser on psoriasis</article-title>
          <source>Arch Dermatol</source>
          <year>1992</year>
          <volume>128</volume>
          <issue>6</issue>
          <fpage>853</fpage>
          <lpage>855</lpage>
          <pub-id pub-id-type="doi">10.1001/archderm.128.6.853</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Hacker SM, Rasmussen JE (1992) The effect of flash lamp-pulsed dye laser on psoriasis. Arch Dermatol 128(6):853&#x2013;855 <pub-id pub-id-type="pmid">1599282</pub-id></citation>
      </ref>
      <ref id="CR101">
        <label>101.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gordon</surname>
              <given-names>KB</given-names>
            </name>
            <name>
              <surname>Papp</surname>
              <given-names>KA</given-names>
            </name>
            <name>
              <surname>Hamilton</surname>
              <given-names>TK</given-names>
            </name>
            <name>
              <surname>Walicke</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Dummer</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Bresnahan</surname>
              <given-names>BW</given-names>
            </name>
            <name>
              <surname>Menter</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial</article-title>
          <source>JAMA</source>
          <year>2003</year>
          <volume>290</volume>
          <issue>23</issue>
          <fpage>3073</fpage>
          <lpage>3080</lpage>
          <pub-id pub-id-type="doi">10.1001/jama.290.23.3073</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Gordon KB, Papp KA, Hamilton TK, Walicke PA, Dummer W, Li N, Bresnahan BW, Menter A (2003) Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 290(23):3073&#x2013;3080 <pub-id pub-id-type="pmid">14679270</pub-id></citation>
      </ref>
      <ref id="CR102">
        <label>102.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lebwohl</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Tyring</surname>
              <given-names>SK</given-names>
            </name>
            <name>
              <surname>Hamilton</surname>
              <given-names>TK</given-names>
            </name>
            <name>
              <surname>Toth</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Glazer</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Tawfik</surname>
              <given-names>NH</given-names>
            </name>
            <name>
              <surname>Walicke</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Dummer</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Garovoy</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Pariser</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>A novel targeted T-cell modulator, efalizumab, for plaque psoriasis</article-title>
          <source>N Engl J Med</source>
          <year>2003</year>
          <volume>349</volume>
          <issue>21</issue>
          <fpage>2004</fpage>
          <lpage>2013</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa030002</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Lebwohl M, Tyring SK, Hamilton TK, Toth D, Glazer S, Tawfik NH, Walicke P, Dummer W, Wang X, Garovoy MR, Pariser D (2003) A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 349(21):2004&#x2013;2013 <pub-id pub-id-type="pmid">14627785</pub-id></citation>
      </ref>
      <ref id="CR103">
        <label>103.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Leonardi</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Papp</surname>
              <given-names>KA</given-names>
            </name>
            <name>
              <surname>Gordon</surname>
              <given-names>KB</given-names>
            </name>
            <name>
              <surname>Menter</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Feldman</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Caro</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Walicke</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Compton</surname>
              <given-names>PG</given-names>
            </name>
            <name>
              <surname>Gottlieb</surname>
              <given-names>AB</given-names>
            </name>
          </person-group>
          <article-title>Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial</article-title>
          <source>J Am Acad Dermatol</source>
          <year>2005</year>
          <volume>52</volume>
          <issue>3 Pt 1</issue>
          <fpage>425</fpage>
          <lpage>433</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jaad.2004.09.029</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Leonardi CL, Papp KA, Gordon KB, Menter A, Feldman SR, Caro I, Walicke PA, Compton PG, Gottlieb AB (2005) Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol 52(3 Pt 1):425&#x2013;433 <pub-id pub-id-type="pmid">15761420</pub-id></citation>
      </ref>
      <ref id="CR104">
        <label>104.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Menter</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gordon</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Carey</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Hamilton</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Glazer</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Caro</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Gulliver</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis</article-title>
          <source>Arch Dermatol</source>
          <year>2005</year>
          <volume>141</volume>
          <issue>1</issue>
          <fpage>31</fpage>
          <lpage>38</lpage>
          <pub-id pub-id-type="doi">10.1001/archderm.141.1.31</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Menter A, Gordon K, Carey W, Hamilton T, Glazer S, Caro I, Li N, Gulliver W (2005) Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol 141(1):31&#x2013;38 <pub-id pub-id-type="pmid">15655139</pub-id></citation>
      </ref>
      <ref id="CR105">
        <label>105.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Papp</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Bissonnette</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Kr&#xFC;ger</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Carey</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Gratton</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Gulliver</surname>
              <given-names>WP</given-names>
            </name>
            <name>
              <surname>Lui</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody</article-title>
          <source>J Am Acad Dermatol</source>
          <year>2001</year>
          <volume>45</volume>
          <issue>5</issue>
          <fpage>665</fpage>
          <lpage>674</lpage>
          <pub-id pub-id-type="doi">10.1067/mjd.2001.117850</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Papp K, Bissonnette R, Kr&#xFC;ger JG, Carey W, Gratton D, Gulliver WP, Lui H (2001) The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody. J Am Acad Dermatol 45(5):665&#x2013;674 <pub-id pub-id-type="pmid">11606914</pub-id></citation>
      </ref>
      <ref id="CR106">
        <label>106.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gottlieb</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Gordon</surname>
              <given-names>KB</given-names>
            </name>
            <name>
              <surname>Lebwohl</surname>
              <given-names>MG</given-names>
            </name>
            <name>
              <surname>Caro</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Walicke</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Leonardi</surname>
              <given-names>CL</given-names>
            </name>
          </person-group>
          <article-title>Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis</article-title>
          <source>J Drugs Dermatol</source>
          <year>2004</year>
          <volume>3</volume>
          <issue>6</issue>
          <fpage>614</fpage>
          <lpage>624</lpage>
        </citation>
        <citation citation-type="display-unstructured">Gottlieb AB, Gordon KB, Lebwohl MG, Caro I, Walicke PA, Li N, Leonardi CL (2004) Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis. J Drugs Dermatol 3(6):614&#x2013;624 <pub-id pub-id-type="pmid">15624744</pub-id></citation>
      </ref>
      <ref id="CR107">
        <label>107.</label>
        <citation citation-type="other">Gottlieb AB, Matheson RT, Lowe N, Krueger GG, Kang S, Goffe BS, Gaspari AA, Ling M, Weinstein GD, Nayak A, Gordon KB, Zitnik R (2003) A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 139(12):1627&#x2013;1632; discussion 1632</citation>
      </ref>
      <ref id="CR108">
        <label>108.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Leonardi</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Powers</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Matheson</surname>
              <given-names>RT</given-names>
            </name>
            <name>
              <surname>Goffe</surname>
              <given-names>BS</given-names>
            </name>
            <name>
              <surname>Zitnik</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gottlieb</surname>
              <given-names>AB</given-names>
            </name>
          </person-group>
          <article-title>Etanercept as monotherapy in patients with psoriasis</article-title>
          <source>N Engl J Med</source>
          <year>2003</year>
          <volume>349</volume>
          <issue>21</issue>
          <fpage>2014</fpage>
          <lpage>2022</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa030409</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, Gottlieb AB (2003) Etanercept as monotherapy in patients with psoriasis. N Engl J Med 349(21):2014&#x2013;2022 <pub-id pub-id-type="pmid">14627786</pub-id></citation>
      </ref>
      <ref id="CR109">
        <label>109.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Costanzo</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Mazzotta</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Papoutsaki</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Nistico</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Chimenti</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Safety and efficacy study on etanercept in patients with plaque psoriasis</article-title>
          <source>Br J Dermatol</source>
          <year>2005</year>
          <volume>152</volume>
          <issue>1</issue>
          <fpage>187</fpage>
          <lpage>189</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2133.2005.06306.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Costanzo A, Mazzotta A, Papoutsaki M, Nistico S, Chimenti S (2005) Safety and efficacy study on etanercept in patients with plaque psoriasis. Br J Dermatol 152(1):187&#x2013;189 <pub-id pub-id-type="pmid">15656833</pub-id></citation>
      </ref>
      <ref id="CR110">
        <label>110.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Antoni</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Krueger</surname>
              <given-names>GG</given-names>
            </name>
            <name>
              <surname>Vlam</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Birbara</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Beutler</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Guzzo</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Zhou</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Dooley</surname>
              <given-names>LT</given-names>
            </name>
            <name>
              <surname>Kavanaugh</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial</article-title>
          <source>Ann Rheum Dis</source>
          <year>2005</year>
          <volume>64</volume>
          <issue>8</issue>
          <fpage>1150</fpage>
          <lpage>1157</lpage>
          <pub-id pub-id-type="doi">10.1136/ard.2004.032268</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, Zhou B, Dooley LT, Kavanaugh A (2005) Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 64(8):1150&#x2013;1157 <pub-id pub-id-type="pmid">15677701</pub-id></citation>
      </ref>
      <ref id="CR111">
        <label>111.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gottlieb</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Evans</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Dooley</surname>
              <given-names>LT</given-names>
            </name>
            <name>
              <surname>Guzzo</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Baker</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Bala</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Marano</surname>
              <given-names>CW</given-names>
            </name>
            <name>
              <surname>Menter</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial</article-title>
          <source>J Am Acad Dermatol</source>
          <year>2004</year>
          <volume>51</volume>
          <issue>4</issue>
          <fpage>534</fpage>
          <lpage>542</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jaad.2004.02.021</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Gottlieb AB, Evans R, Li S, Dooley LT, Guzzo CA, Baker D, Bala M, Marano CW, Menter A (2004) Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 51(4):534&#x2013;542 <pub-id pub-id-type="pmid">15389187</pub-id></citation>
      </ref>
      <ref id="CR112">
        <label>112.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chaudhari</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Romano</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Mulcahy</surname>
              <given-names>LD</given-names>
            </name>
            <name>
              <surname>Dooley</surname>
              <given-names>LT</given-names>
            </name>
            <name>
              <surname>Baker</surname>
              <given-names>DG</given-names>
            </name>
            <name>
              <surname>Gottlieb</surname>
              <given-names>AB</given-names>
            </name>
          </person-group>
          <article-title>Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial</article-title>
          <source>Lancet</source>
          <year>2001</year>
          <volume>357</volume>
          <issue>9271</issue>
          <fpage>1842</fpage>
          <lpage>1847</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(00)04954-0</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB (2001) Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 357(9271):1842&#x2013;1847 <pub-id pub-id-type="pmid">11410193</pub-id></citation>
      </ref>
      <ref id="CR113">
        <label>113.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schopf</surname>
              <given-names>RE</given-names>
            </name>
            <name>
              <surname>Aust</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Knop</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab</article-title>
          <source>J Am Acad Dermatol</source>
          <year>2002</year>
          <volume>46</volume>
          <issue>6</issue>
          <fpage>886</fpage>
          <lpage>891</lpage>
          <pub-id pub-id-type="doi">10.1067/mjd.2002.120472</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Schopf RE, Aust H, Knop J (2002) Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab. J Am Acad Dermatol 46(6):886&#x2013;891 <pub-id pub-id-type="pmid">12063486</pub-id></citation>
      </ref>
      <ref id="CR114">
        <label>114.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Koo</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis. OLP302 Study Group</article-title>
          <source>Br J Dermatol</source>
          <year>1998</year>
          <volume>139</volume>
          <issue>1</issue>
          <fpage>88</fpage>
          <lpage>95</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1365-2133.1998.02319.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Koo J (1998) A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis. OLP302 Study Group. Br J Dermatol 139(1):88&#x2013;95 <pub-id pub-id-type="pmid">9764154</pub-id></citation>
      </ref>
      <ref id="CR115">
        <label>115.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thaci</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Brautigam</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kaufmann</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Weidinger</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Paul</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Christophers</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Body-weight-independent dosing of cyclosporine micro-emulsion and three times weekly maintenance regimen in severe psoriasis. A randomised study</article-title>
          <source>Dermatology</source>
          <year>2002</year>
          <volume>205</volume>
          <issue>4</issue>
          <fpage>383</fpage>
          <lpage>388</lpage>
          <pub-id pub-id-type="doi">10.1159/000066425</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Thaci D, Brautigam M, Kaufmann R, Weidinger G, Paul C, Christophers E (2002) Body-weight-independent dosing of cyclosporine micro-emulsion and three times weekly maintenance regimen in severe psoriasis. A randomised study. Dermatology 205(4):383&#x2013;388 <pub-id pub-id-type="pmid">12444336</pub-id></citation>
      </ref>
      <ref id="CR116">
        <label>116.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mahrle</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Schulze</surname>
              <given-names>HG</given-names>
            </name>
            <name>
              <surname>F&#xE4;rber</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Weidinger</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Steigleder</surname>
              <given-names>GK</given-names>
            </name>
          </person-group>
          <article-title>Low-dose short-term cyclosporine versus etretinate in psoriasis: improvement of skin, nail and joint involvement</article-title>
          <source>J Am Acad Dermatol</source>
          <year>1995</year>
          <volume>32</volume>
          <issue>1</issue>
          <fpage>78</fpage>
          <lpage>88</lpage>
          <pub-id pub-id-type="doi">10.1016/0190-9622(95)90189-2</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Mahrle G, Schulze HG, F&#xE4;rber L, Weidinger G, Steigleder GK (1995) Low-dose short-term cyclosporine versus etretinate in psoriasis: improvement of skin, nail and joint involvement. J Am Acad Dermatol 32(1):78&#x2013;88 <pub-id pub-id-type="pmid">7822521</pub-id></citation>
      </ref>
      <ref id="CR117">
        <label>117.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ellis</surname>
              <given-names>CN</given-names>
            </name>
            <name>
              <surname>Fradin</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Messana</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Siegel</surname>
              <given-names>MT</given-names>
            </name>
            <name>
              <surname>Howland Hartley</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial</article-title>
          <source>N Engl J Med</source>
          <year>1991</year>
          <volume>324</volume>
          <fpage>277</fpage>
          <lpage>284</lpage>
        </citation>
        <citation citation-type="display-unstructured">Ellis CN, Fradin MS, Messana JM, Brown MD, Siegel MT, Howland Hartley A (1991) Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. N Engl J Med 324:277&#x2013;284 <pub-id pub-id-type="pmid">1986287</pub-id></citation>
      </ref>
      <ref id="CR118">
        <label>118.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Elder</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Moore</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Chang</surname>
              <given-names>CT</given-names>
            </name>
            <name>
              <surname>Jin</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Charnick</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Nedelman</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Cohen</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Guzzo</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Lowe</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Simpson</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Efficacy and pharmacokinetics of two formulations of cyclosporine in patients with psoriasis</article-title>
          <source>J Clin Pharmacol</source>
          <year>1995</year>
          <volume>35</volume>
          <fpage>865</fpage>
          <lpage>875</lpage>
        </citation>
        <citation citation-type="display-unstructured">Elder C, Moore M, Chang CT, Jin J, Charnick S, Nedelman J, Cohen A, Guzzo C, Lowe N, Simpson K (1995) Efficacy and pharmacokinetics of two formulations of cyclosporine in patients with psoriasis. J Clin Pharmacol 35:865&#x2013;875 <pub-id pub-id-type="pmid">8786246</pub-id></citation>
      </ref>
      <ref id="CR119">
        <label>119.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Engst</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Huber</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Ergebnisse einer Cyclosporin-behandlung bei schwerer, chronischer Psoriasis vulgaris</article-title>
          <source>Hautarzt</source>
          <year>1989</year>
          <volume>40</volume>
          <fpage>186</fpage>
          <lpage>189</lpage>
        </citation>
        <citation citation-type="display-unstructured">Engst R, Huber J (1989) Ergebnisse einer Cyclosporin-behandlung bei schwerer, chronischer Psoriasis vulgaris. Hautarzt 40:186&#x2013;189 </citation>
      </ref>
      <ref id="CR120">
        <label>120.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Laburte</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Grossman</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Abi-Rached</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Abeywickrama</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Dubertret</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Efficacy and safety of oral cyclosporine A (CYA; Sandimmun) for long-term treatment of chronic severe plaque psoriasis</article-title>
          <source>Br J Dermatol</source>
          <year>1994</year>
          <volume>130</volume>
          <fpage>366</fpage>
          <lpage>375</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2133.1994.tb02935.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Laburte C, Grossman R, Abi-Rached J, Abeywickrama KM, Dubertret L (1994) Efficacy and safety of oral cyclosporine A (CYA; Sandimmun) for long-term treatment of chronic severe plaque psoriasis. Br J Dermatol 130:366&#x2013;375 <pub-id pub-id-type="pmid">8148280</pub-id></citation>
      </ref>
      <ref id="CR121">
        <label>121.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Meffert</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Braeutigam</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Faerber</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Weidinger</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Low-dose (1,25mg/kg) cyclosporine A: treatment of psoriasis and investigation of the influence on lipid profile</article-title>
          <source>Acta Derm Venereol Suppl</source>
          <year>1997</year>
          <volume>77</volume>
          <fpage>137</fpage>
          <lpage>141</lpage>
        </citation>
        <citation citation-type="display-unstructured">Meffert H, Braeutigam M, Faerber L, Weidinger G (1997) Low-dose (1,25mg/kg) cyclosporine A: treatment of psoriasis and investigation of the influence on lipid profile. Acta Derm Venereol Suppl 77:137&#x2013;141 </citation>
      </ref>
      <ref id="CR122">
        <label>122.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Finzi</surname>
              <given-names>AF</given-names>
            </name>
            <name>
              <surname>Mozzanica</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Pigatto</surname>
              <given-names>PD</given-names>
            </name>
            <name>
              <surname>Cattaneo</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ippolito</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Cyclosporine versus etretinate: Italian multicentre comparative trial in severe psoriasis</article-title>
          <source>Dermatology</source>
          <year>1993</year>
          <volume>187</volume>
          <issue>Suppl 1</issue>
          <fpage>8</fpage>
          <lpage>18</lpage>
        </citation>
        <citation citation-type="display-unstructured">Finzi AF, Mozzanica N, Pigatto PD, Cattaneo A, Ippolito F (1993) Cyclosporine versus etretinate: Italian multicentre comparative trial in severe psoriasis. Dermatology 187(Suppl 1):8&#x2013;18 <pub-id pub-id-type="pmid">8369579</pub-id></citation>
      </ref>
      <ref id="CR123">
        <label>123.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Heydendael</surname>
              <given-names>VM</given-names>
            </name>
            <name>
              <surname>Spuls</surname>
              <given-names>PI</given-names>
            </name>
            <name>
              <surname>Opmeer</surname>
              <given-names>BC</given-names>
            </name>
            <name>
              <surname>Borgie</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Reitsma</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Goldschmidt</surname>
              <given-names>WF</given-names>
            </name>
            <name>
              <surname>Bossuyt</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Bos</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Rie</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
          <article-title>Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis</article-title>
          <source>N Engl J Med</source>
          <year>2003</year>
          <volume>349</volume>
          <issue>7</issue>
          <fpage>658</fpage>
          <lpage>665</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa021359</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Heydendael VM, Spuls PI, Opmeer BC, de Borgie CA, Reitsma JB, Goldschmidt WF, Bossuyt PM, Bos JD, de Rie MA (2003) Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 349(7):658&#x2013;665 <pub-id pub-id-type="pmid">12917302</pub-id></citation>
      </ref>
      <ref id="CR124">
        <label>124.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Reitamo</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Spuls</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Sassolas</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Lahfa</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Claudy</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Griffiths</surname>
              <given-names>CE</given-names>
            </name>
          </person-group>
          <article-title>Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial</article-title>
          <source>Br J Dermatol</source>
          <year>2001</year>
          <volume>145</volume>
          <issue>3</issue>
          <fpage>438</fpage>
          <lpage>445</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1365-2133.2001.04376.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Reitamo S, Spuls P, Sassolas B, Lahfa M, Claudy A, Griffiths CE (2001) Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial. Br J Dermatol 145(3):438&#x2013;445 <pub-id pub-id-type="pmid">11531834</pub-id></citation>
      </ref>
      <ref id="CR125">
        <label>125.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Grossman</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Thivolet</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Claudy</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Souteyrand</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Guilhou</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Thomas</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Amblard</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Belaich</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Belilovsky</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Brassinne</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A novel therapeutic approach to psoriasis with combination calcipotriol ointment and very low-dose cyclosporine: results of a multicenter placebo-controlled study</article-title>
          <source>J Am Acad Dermatol</source>
          <year>1994</year>
          <volume>31</volume>
          <issue>1</issue>
          <fpage>68</fpage>
          <lpage>74</lpage>
        </citation>
        <citation citation-type="display-unstructured">Grossman RM, Thivolet J, Claudy A, Souteyrand P, Guilhou JJ, Thomas P, Amblard P, Belaich S, de Belilovsky C, de la Brassinne M et al (1994) A novel therapeutic approach to psoriasis with combination calcipotriol ointment and very low-dose cyclosporine: results of a multicenter placebo-controlled study. J Am Acad Dermatol 31(1):68&#x2013;74 <pub-id pub-id-type="pmid">8021375</pub-id></citation>
      </ref>
      <ref id="CR126">
        <label>126.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Finzi</surname>
              <given-names>AF</given-names>
            </name>
            <name>
              <surname>Mozzanica</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Cattaneo</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Chiappino</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Pigatto</surname>
              <given-names>PD</given-names>
            </name>
          </person-group>
          <article-title>Effectiveness of cyclosporine treatment in severe psoriasis: A clinical and immunologic study</article-title>
          <source>J Am Acad Dermatol</source>
          <year>1989</year>
          <volume>21</volume>
          <fpage>91</fpage>
          <lpage>97</lpage>
        </citation>
        <citation citation-type="display-unstructured">Finzi AF, Mozzanica N, Cattaneo A, Chiappino G, Pigatto PD (1989) Effectiveness of cyclosporine treatment in severe psoriasis: A clinical and immunologic study. J Am Acad Dermatol 21:91&#x2013;97 <pub-id pub-id-type="pmid">2787338</pub-id></citation>
      </ref>
      <ref id="CR127">
        <label>127.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Higgins</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Munro</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Marks</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Friedmann</surname>
              <given-names>PS</given-names>
            </name>
            <name>
              <surname>Shuster</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Relapse rates in moderately severe chronic psoriasis treated with cyclosporine A</article-title>
          <source>Br J Dermatol</source>
          <year>1989</year>
          <volume>121</volume>
          <fpage>71</fpage>
          <lpage>74</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2133.1989.tb01402.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Higgins E, Munro C, Marks J, Friedmann PS, Shuster S (1989) Relapse rates in moderately severe chronic psoriasis treated with cyclosporine A. Br J Dermatol 121:71&#x2013;74 <pub-id pub-id-type="pmid">2757958</pub-id></citation>
      </ref>
      <ref id="CR128">
        <label>128.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Litjens</surname>
              <given-names>NH</given-names>
            </name>
            <name>
              <surname>Nibbering</surname>
              <given-names>PH</given-names>
            </name>
            <name>
              <surname>Barrois</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Zomerdijk</surname>
              <given-names>TP</given-names>
            </name>
            <name>
              <surname>Oudenrijn</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Noz</surname>
              <given-names>KC</given-names>
            </name>
            <name>
              <surname>Rademaker</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Meide</surname>
              <given-names>PH</given-names>
            </name>
            <name>
              <surname>Dissel</surname>
              <given-names>JT</given-names>
            </name>
            <name>
              <surname>Thio</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Beneficial effects of fumarate therapy in psoriasis vulgaris patients coincide with downregulation of type 1 cytokines</article-title>
          <source>Br J Dermatol</source>
          <year>2003</year>
          <volume>148</volume>
          <issue>3</issue>
          <fpage>444</fpage>
          <lpage>451</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1365-2133.2003.05153.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Litjens NH, Nibbering PH, Barrois AJ, Zomerdijk TP, Van Den Oudenrijn AC, Noz KC, Rademaker M, Van De Meide PH, Van Dissel JT, Thio B (2003) Beneficial effects of fumarate therapy in psoriasis vulgaris patients coincide with downregulation of type 1 cytokines. Br J Dermatol 148(3):444&#x2013;451 <pub-id pub-id-type="pmid">12653735</pub-id></citation>
      </ref>
      <ref id="CR129">
        <label>129.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Altmeyer</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Matthes</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Pawlak</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Hoffmann</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Frosch</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Ruppert</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Wassilew</surname>
              <given-names>SW</given-names>
            </name>
            <name>
              <surname>Horn</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kreysel</surname>
              <given-names>HW</given-names>
            </name>
            <name>
              <surname>Lutz</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Barth</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Rietzschel</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Joshi</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Antipsoriatic effect of fumaric acid derivatives. Results of a multicentre double-blind study in 100 patients</article-title>
          <source>J Am Acad Dermatol</source>
          <year>1994</year>
          <volume>30</volume>
          <issue>6</issue>
          <fpage>977</fpage>
          <lpage>981</lpage>
        </citation>
        <citation citation-type="display-unstructured">Altmeyer PJ, Matthes U, Pawlak F, Hoffmann K, Frosch PJ, Ruppert P, Wassilew SW, Horn T, Kreysel HW, Lutz G, Barth J, Rietzschel I, Joshi R (1994) Antipsoriatic effect of fumaric acid derivatives. Results of a multicentre double-blind study in 100 patients. J Am Acad Dermatol 30(6):977&#x2013;981 <pub-id pub-id-type="pmid">8188891</pub-id></citation>
      </ref>
      <ref id="CR130">
        <label>130.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gollnick</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Altmeyer</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Kaufmann</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Ring</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Christophers</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Pavel</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ziegler</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Topical calcipotriol plus oral fumaric acid is more effective and faster acting than oral fumaric acid monotherapy in the treatment of severe chronic plaque psoriasis vulgaris</article-title>
          <source>Dermatology</source>
          <year>2002</year>
          <volume>205</volume>
          <issue>1</issue>
          <fpage>46</fpage>
          <lpage>53</lpage>
          <pub-id pub-id-type="doi">10.1159/000063148</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Gollnick H, Altmeyer P, Kaufmann R, Ring J, Christophers E, Pavel S, Ziegler J (2002) Topical calcipotriol plus oral fumaric acid is more effective and faster acting than oral fumaric acid monotherapy in the treatment of severe chronic plaque psoriasis vulgaris. Dermatology 205(1):46&#x2013;53 <pub-id pub-id-type="pmid">12145434</pub-id></citation>
      </ref>
      <ref id="CR131">
        <label>131.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kolbach</surname>
              <given-names>DN</given-names>
            </name>
            <name>
              <surname>Nieboer</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Fumaric acid therapy in psoriasis: results and side effects of 2 years of treatment</article-title>
          <source>J Am Acad Dermatol</source>
          <year>1992</year>
          <volume>27</volume>
          <issue>5 Pt 1</issue>
          <fpage>769</fpage>
          <lpage>771</lpage>
        </citation>
        <citation citation-type="display-unstructured">Kolbach DN, Nieboer C (1992) Fumaric acid therapy in psoriasis: results and side effects of 2 years of treatment. J Am Acad Dermatol 27(5 Pt 1):769&#x2013;771 <pub-id pub-id-type="pmid">1430403</pub-id></citation>
      </ref>
      <ref id="CR132">
        <label>132.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nugteren-Huying</surname>
              <given-names>WM</given-names>
            </name>
            <name>
              <surname>Schroeff JGvd</surname>
            </name>
            <name>
              <surname>Hermans</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Suurmond</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Fumaric acid therapy for psoriasis: a randomized, double-blind, placeFumaric acid therapy for psoriasis: a randomized, double-bo-controlled study</article-title>
          <source>J Am Acad Dermatol</source>
          <year>1990</year>
          <volume>22</volume>
          <fpage>311</fpage>
          <lpage>312</lpage>
        </citation>
        <citation citation-type="display-unstructured">Nugteren-Huying WM, Schroeff JGvd, Hermans J, Suurmond D (1990) Fumaric acid therapy for psoriasis: a randomized, double-blind, placeFumaric acid therapy for psoriasis: a randomized, double-bo-controlled study. J Am Acad Dermatol 22:311&#x2013;312 <pub-id pub-id-type="pmid">2312814</pub-id></citation>
      </ref>
      <ref id="CR133">
        <label>133.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Altmeyer</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Hartwig</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Matthes</surname>
              <given-names>U</given-names>
            </name>
          </person-group>
          <article-title>Das Wirkungs-und Sicherheitsprofil von Fumars&#xE4;ureestern in der oralen Langzeittherapie bei schwerer therapieresistenter Psoriasis vulgaris. Eine Untersuchung an 83 Patienten</article-title>
          <source>Hautarzt</source>
          <year>1996</year>
          <volume>47</volume>
          <issue>3</issue>
          <fpage>190</fpage>
          <lpage>196</lpage>
          <pub-id pub-id-type="doi">10.1007/s001050050401</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Altmeyer P, Hartwig R, Matthes U (1996) Das Wirkungs-und Sicherheitsprofil von Fumars&#xE4;ureestern in der oralen Langzeittherapie bei schwerer therapieresistenter Psoriasis vulgaris. Eine Untersuchung an 83 Patienten. Hautarzt 47(3):190&#x2013;196 <pub-id pub-id-type="pmid">8647701</pub-id></citation>
      </ref>
      <ref id="CR134">
        <label>134.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bayard</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Hunziker</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Krebs</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Speiser</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Joshi</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Peroral long-term treatment of psoriasis using fumaric acid derivative</article-title>
          <source>Hautarzt</source>
          <year>1987</year>
          <volume>38</volume>
          <issue>5</issue>
          <fpage>279</fpage>
          <lpage>285</lpage>
        </citation>
        <citation citation-type="display-unstructured">Bayard W, Hunziker T, Krebs A, Speiser P, Joshi R (1987) Peroral long-term treatment of psoriasis using fumaric acid derivative. Hautarzt 38(5):279&#x2013;285 <pub-id pub-id-type="pmid">3112040</pub-id></citation>
      </ref>
      <ref id="CR135">
        <label>135.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Carboni</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Felice</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Simoni</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Soda</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Chimenti</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Fumaric acid esters in the treatment of psoriasis: an Italian experience</article-title>
          <source>J Dermatol Treat</source>
          <year>2004</year>
          <volume>15</volume>
          <issue>1</issue>
          <fpage>23</fpage>
          <lpage>26</lpage>
          <pub-id pub-id-type="doi">10.1080/09546630310019346</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Carboni I, De Felice C, De Simoni I, Soda R, Chimenti S (2004) Fumaric acid esters in the treatment of psoriasis: an Italian experience. J Dermatol Treat 15(1):23&#x2013;26 </citation>
      </ref>
      <ref id="CR136">
        <label>136.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mrowietz</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Christophers</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Altmeyer</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study. German Multicentre Study</article-title>
          <source>Br J Dermatol</source>
          <year>1998</year>
          <volume>138</volume>
          <issue>3</issue>
          <fpage>456</fpage>
          <lpage>460</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1365-2133.1998.02124.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Mrowietz U, Christophers E, Altmeyer P (1998) Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study. German Multicentre Study. Br J Dermatol 138(3):456&#x2013;460 <pub-id pub-id-type="pmid">9580799</pub-id></citation>
      </ref>
      <ref id="CR137">
        <label>137.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Roenigk</surname>
              <given-names>HH</given-names>
            </name>
            <name>
              <surname>Auerbach</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Maibach</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Weinstein</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Lebwohl</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Methotrexate in psoriasis: consensus conference</article-title>
          <source>J Am Acad Dermatol</source>
          <year>1998</year>
          <volume>38</volume>
          <issue>3</issue>
          <fpage>478</fpage>
          <lpage>485</lpage>
          <pub-id pub-id-type="doi">10.1016/S0190-9622(98)70508-0</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Roenigk HH Jr, Auerbach R, Maibach H, Weinstein G, Lebwohl M (1998) Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol 38(3):478&#x2013;485 <pub-id pub-id-type="pmid">9520032</pub-id></citation>
      </ref>
      <ref id="CR138">
        <label>138.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Weinstein</surname>
              <given-names>GD</given-names>
            </name>
            <name>
              <surname>Frost</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Methotrexate for psoriasis. A new therapeutic schedule</article-title>
          <source>Arch Dermatol</source>
          <year>1971</year>
          <volume>103</volume>
          <fpage>33</fpage>
          <lpage>38</lpage>
          <pub-id pub-id-type="doi">10.1001/archderm.103.1.33</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Weinstein GD, Frost P (1971) Methotrexate for psoriasis. A new therapeutic schedule. Arch Dermatol 103:33&#x2013;38 <pub-id pub-id-type="pmid">5539502</pub-id></citation>
      </ref>
      <ref id="CR139">
        <label>139.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nyfors</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Brodthagen</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Methotrexate for psoriasis in weekly oral doses without any adjunctive therapy</article-title>
          <source>Dermatologica</source>
          <year>1970</year>
          <volume>140</volume>
          <fpage>345</fpage>
          <lpage>355</lpage>
        </citation>
        <citation citation-type="display-unstructured">Nyfors A, Brodthagen H (1970) Methotrexate for psoriasis in weekly oral doses without any adjunctive therapy. Dermatologica 140:345&#x2013;355 <pub-id pub-id-type="pmid">5471371</pub-id></citation>
      </ref>
      <ref id="CR140">
        <label>140.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kerkhof</surname>
              <given-names>PC</given-names>
            </name>
            <name>
              <surname>Cambazard</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Hutchinson</surname>
              <given-names>PE</given-names>
            </name>
            <name>
              <surname>Haneke</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Wong</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Souteyrand</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Damstra</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Combemale</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Neumann</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Chalmers</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Olsen</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Revuz</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>The effect of addition of calcipotriol ointment (50&#xA0;micrograms/g) to acitretin therapy in psoriasis</article-title>
          <source>Br J Dermatol</source>
          <year>1998</year>
          <volume>138</volume>
          <issue>1</issue>
          <fpage>84</fpage>
          <lpage>89</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1365-2133.1998.02030.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">van de Kerkhof PC, Cambazard F, Hutchinson PE, Haneke E, Wong E, Souteyrand P, Damstra RJ, Combemale P, Neumann MH, Chalmers RJ, Olsen L, Revuz J (1998) The effect of addition of calcipotriol ointment (50&#xA0;micrograms/g) to acitretin therapy in psoriasis. Br J Dermatol 138(1):84&#x2013;89 <pub-id pub-id-type="pmid">9536227</pub-id></citation>
      </ref>
      <ref id="CR141">
        <label>141.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kragballe</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Jansen</surname>
              <given-names>CT</given-names>
            </name>
            <name>
              <surname>Geiger</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Bjerke</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Falk</surname>
              <given-names>ES</given-names>
            </name>
            <name>
              <surname>Gip</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Hjorth</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Lauharanta</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Mork</surname>
              <given-names>NJ</given-names>
            </name>
            <name>
              <surname>Reunala</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A double-blind comparison of acitretin and etretinate in the treatment of severe psoriasis. Results of a Nordic multicentre study</article-title>
          <source>Acta Derm Venereol</source>
          <year>1989</year>
          <volume>69</volume>
          <issue>1</issue>
          <fpage>35</fpage>
          <lpage>40</lpage>
        </citation>
        <citation citation-type="display-unstructured">Kragballe K, Jansen CT, Geiger JM, Bjerke JR, Falk ES, Gip L, Hjorth N, Lauharanta J, Mork NJ, Reunala T et al (1989) A double-blind comparison of acitretin and etretinate in the treatment of severe psoriasis. Results of a Nordic multicentre study Acta Derm Venereol 69(1):35&#x2013;40 <pub-id pub-id-type="pmid">2563606</pub-id></citation>
      </ref>
      <ref id="CR142">
        <label>142.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gupta</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Goldfarb</surname>
              <given-names>MT</given-names>
            </name>
            <name>
              <surname>Ellis</surname>
              <given-names>CN</given-names>
            </name>
            <name>
              <surname>Voorhees</surname>
              <given-names>JJ</given-names>
            </name>
          </person-group>
          <article-title>Side-effect profile of acitretin therapy in psoriasis</article-title>
          <source>J Am Acad Dermatol</source>
          <year>1989</year>
          <volume>20</volume>
          <issue>6</issue>
          <fpage>1088</fpage>
          <lpage>1093</lpage>
        </citation>
        <citation citation-type="display-unstructured">Gupta AK, Goldfarb MT, Ellis CN, Voorhees JJ (1989) Side-effect profile of acitretin therapy in psoriasis. J Am Acad Dermatol 20(6):1088&#x2013;1093 <pub-id pub-id-type="pmid">2526824</pub-id></citation>
      </ref>
      <ref id="CR143">
        <label>143.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Carlin</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Callis</surname>
              <given-names>KP</given-names>
            </name>
            <name>
              <surname>Krueger</surname>
              <given-names>GG</given-names>
            </name>
          </person-group>
          <article-title>Efficacy of acitretin and commercial tanning bed therapy for psoriasis</article-title>
          <source>Arch Dermatol</source>
          <year>2003</year>
          <volume>139</volume>
          <issue>4</issue>
          <fpage>436</fpage>
          <lpage>442</lpage>
          <pub-id pub-id-type="doi">10.1001/archderm.139.4.436</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Carlin CS, Callis KP, Krueger GG (2003) Efficacy of acitretin and commercial tanning bed therapy for psoriasis. Arch Dermatol 139(4):436&#x2013;442 <pub-id pub-id-type="pmid">12707089</pub-id></citation>
      </ref>
      <ref id="CR144">
        <label>144.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Halevy</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Giryes</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Friger</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Sukenik</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Dead sea bath salt for the treatment of psoriasis vulgaris: a double- blind controlled study</article-title>
          <source>J Eur Acad Dermatol Venereol</source>
          <year>1997</year>
          <volume>9</volume>
          <issue>3</issue>
          <fpage>237</fpage>
          <lpage>242</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1468-3083.1997.tb00509.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Halevy S, Giryes H, Friger M, Sukenik H (1997) Dead sea bath salt for the treatment of psoriasis vulgaris: a double- blind controlled study. J Eur Acad Dermatol Venereol 9(3):237&#x2013;242 </citation>
      </ref>
      <ref id="CR145">
        <label>145.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Robertson</surname>
              <given-names>DB</given-names>
            </name>
            <name>
              <surname>McCarty</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Jarratt</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Treatment of psoriasis with 8-methoxypsoralen and sunlight</article-title>
          <source>South Med J</source>
          <year>1978</year>
          <volume>71</volume>
          <issue>11</issue>
          <fpage>1345</fpage>
          <lpage>1349</lpage>
        </citation>
        <citation citation-type="display-unstructured">Robertson DB, McCarty JR, Jarratt M (1978) Treatment of psoriasis with 8-methoxypsoralen and sunlight. South Med J 71(11):1345&#x2013;1349 <pub-id pub-id-type="pmid">362536</pub-id></citation>
      </ref>
      <ref id="CR146">
        <label>146.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fleischer</surname>
              <given-names>ABJ</given-names>
            </name>
            <name>
              <surname>Clark</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Rapp</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Reboussin</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Feldman</surname>
              <given-names>SR</given-names>
            </name>
          </person-group>
          <article-title>Commercial tanning bed treatment is an effective psoriasis treatment:results from an uncontrolled clinical trial</article-title>
          <source>J Invest Dermatol</source>
          <year>1997</year>
          <volume>109</volume>
          <issue>2</issue>
          <fpage>170</fpage>
          <lpage>174</lpage>
          <pub-id pub-id-type="doi">10.1111/1523-1747.ep12319272</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Fleischer ABJ, Clark AR, Rapp SR, Reboussin DM, Feldman SR (1997) Commercial tanning bed treatment is an effective psoriasis treatment:results from an uncontrolled clinical trial. J Invest Dermatol 109(2):170&#x2013;174 <pub-id pub-id-type="pmid">9242503</pub-id></citation>
      </ref>
      <ref id="CR147">
        <label>147.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fortune</surname>
              <given-names>DG</given-names>
            </name>
            <name>
              <surname>Richards</surname>
              <given-names>HL</given-names>
            </name>
            <name>
              <surname>Kirby</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Bowcock</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Main</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Griffiths</surname>
              <given-names>CE</given-names>
            </name>
          </person-group>
          <article-title>A cognitive-behavioural symptom management programme as an adjunct in psoriasis therapy</article-title>
          <source>Br J Dermatol</source>
          <year>2002</year>
          <volume>146</volume>
          <issue>3</issue>
          <fpage>458</fpage>
          <lpage>465</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1365-2133.2002.04622.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Fortune DG, Richards HL, Kirby B, Bowcock S, Main CJ, Griffiths CE (2002) A cognitive-behavioural symptom management programme as an adjunct in psoriasis therapy. Br J Dermatol 146(3):458&#x2013;465 <pub-id pub-id-type="pmid">11952546</pub-id></citation>
      </ref>
      <ref id="CR148">
        <label>148.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tausk</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Whitmore</surname>
              <given-names>SE</given-names>
            </name>
          </person-group>
          <article-title>A pilot study of hypnosis in the treatment of patients with psoriasis</article-title>
          <source>Psychother Psychosom</source>
          <year>1999</year>
          <volume>68</volume>
          <issue>4</issue>
          <fpage>221</fpage>
          <lpage>225</lpage>
          <pub-id pub-id-type="doi">10.1159/000012336</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Tausk F, Whitmore SE (1999) A pilot study of hypnosis in the treatment of patients with psoriasis. Psychother Psychosom 68(4):221&#x2013;225 <pub-id pub-id-type="pmid">10396014</pub-id></citation>
      </ref>
      <ref id="CR149">
        <label>149.</label>
        <citation citation-type="other">Nast A, Kopp I, Augustin M), Banditt KB, Boehncke WH, Follmann M, Friedrich M, Huber M, Kahl C, Klaus J, Koza J, Kreiselmaier I, Mohr J, Mrowietz U, Ockenfels HM, Orzechowski HD, Prinz J, Reich K, Rosenbach T, Rosumeck S, Schlaeger M, Schmid-Ott G, Sebastian M, Streit V, Weberschock T, Rzany B (2006) S3-Leitlinie zur Therapie der Psoriasis vulgaris. JDDG Suppl 2:S1&#x2013;S126</citation>
      </ref>
    </ref-list>
    <fn-group>
      <fn>
        <p>With kind permission of Deutsche Dermatologische Gesellschaft.</p>
      </fn>
      <fn>
        <p>An enhanced version of these guidelines has been published with Blackwell in 2006.</p>
      </fn>
    </fn-group>
  </back>
</article>
</pmc-articleset>